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                                                    Abstract 
 
The response of tumor intracellular pH to a pharmacological challenge could help identify 
aggressive cancer. pHi is important in the maintenance of normal cell function and is normally 
maintained within a narrow range by the activity of transporters located at the plasma membrane. 
Modulation of tumor pHi may influence proliferation, apoptosis, chemotherapy resistance, and 
thermosensitivity. Chemical exchange saturation transfer (CEST) is a novel MRI contrast 
mechanism that is dependent on cellular pH. Amine and amide concentration-independent 
detection (AACID) is a recently developed CEST contrast method that is intracellular pH (pHi) 
weighted.  
The overall goal of this thesis was to maximize the magnitude of intracellular tumor acidification 
using pharmacologic agents.  To this end, a series of studies were performed to quantify the 
magnitude of acute pHi change in glioblastoma after the injection of a single dose of drugs 
known to interfere with pH regulation.  In addition, we attempted to simulatenously block five 
pH regulatory mechanisms while also providing glucose as an energy substrate to maximize 
tumor acidification.  We hypothesized that this approach would increase the acute pH 
modulation effect. Using a 9.4T MRI scanner CEST spectra were acquired sensitive to pHi using 
amine / amide concentration independen detection (AACID). 
For these experiments a number of different drugs were utilized.  Dichloroacetate (DCA) can 
alter tumor pHi by inhibiting the enzyme pyruvate dehydrogenase kinase causing reduced lactate 
(increasing pHi), or by decreasing the expression of monocarboxylate transporters and vacuolar 
ATPase leading to reduced pHi in tumors. The sodium proton exchanger (NHE1) plays a 
significant role in maintaining pH balance in the tumor microenvironment. Cariporide is a 
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sodium proton exchange inhibitor and has been shown to suppress the invasion and migration of 
cancer cells. Quercetin is an inhibitor of monocarboxylate transporters (MCTs). It specifically 
inhibits MCT1 and MCT2. Pantoprazole is a proton pump inhibitor (PPI) that targets the 
vacuolar H+-ATPase and has been shown to decrease intracellular pH and increase apoptotic cell 
death in cancer cells. Finally, acetazolamide inhibits carbonic anhydrase activity and decreases 
expression of the  aquaporin-1 (AQP1) water channel.  
In the first study, one hour after DCA intravenous injection (200 mg/kg) there was a significant 
increase in tumor AACID level by 0.04±0.01 corresponding to a 0.16 decrease in pHi, and no 
change in AACID in contralateral tissue. In a second study, two hours after cariporide 
intraperitoneal injection there was a significant 0.12±0.03 increase in tumor AACID value 
corresponding to a 0.48 decrease in pHi, and no change in AACID value in contralateral tissue. 
In a final study, two hours after combined intraperitoneal injection of all five drugs, there was a 
significant 0.10±0.03 increase in tumor AACID corresponding to a 0.40 decrease in pHi.  After 
injecting the drug combination with glucose the AACID value increased by 0.18±0.03 
corresponding to a 0.72 decrease in pHi. AACID values were unchanged in contralateral tissue. 
The combined drug treatment with glucose produced the largest acute CEST MRI contrast 
indicating tumor acidification. This approach could be used to help localize brain cancer and 
monitor tumor response to chemotherapy. The use of the approved drugs in combination with pH 
weighted MRI represents a unique approach to cancer detection does not require injection of an 
imaging contrast agent. 
Keywords: Brain cancer; Glioblastoma multiforme(GBM); Apoptosis; pH; MRI; CEST 
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Fig 2.3 Average AACID values in tumor and contralateral ROIs: a) pre and post 
intravenous PBS injection as control (N=3). b) pre and post DCA 200 mg/kg intravenous 
injection (N=6). Error bars represent the standard error of the mean. The asterisks indicated 
p<0.05 in repeated measures t-test. 
 
Figure 1.4 pH control systems in cancer and normal cells. intracellular alkalinisation is a key 
factor in cancer cells for cells transformation. pH-gradient is reversed in cancer cells 
compared to the normal cells. Na+/H+, MCT (monocarboxylate transporter), CA (carbonic 
anhydrase) and V-ATPase (vacuolar-ATPase) are the most important transporters and the 
exchangers that cause intracellular alkalinisation of the cancer cells. 
Figure 1.3 Normal mouse brain: a) coronal fast spin-echo anatomical image showing a 
manually defined region of interest (sold white line), b) the CEST spectrum corresponding 
to the tissue within the ROI shows visible CEST effects at 2 ppm and 3.5 ppm.  
Fig 2.1 Mouse brain with GBM tumor 14 days after implantation: a) baseline AACID map 
prior to PBS intravenous injection, b) the AACID map one hour post PBS intravenous 
injection c) coronal fast spin-echo anatomical image shows regions of interest (ROIs) in the 
tumor (dashed white line) and on the contralateral side (solid white line) and d) AACID 
difference maps for the same brain post-pre PBS injection. 
Fig 2.2 Mouse brain with GBM tumor 14 days after implantation: a) baseline AACID map 
prior to DCA intravenous injection, b) the AACID map one hour post DCA intravenous 
injection c) coronal fast spin-echo anatomical image shows regions of interest (ROIs) in the 
tumor (dashed white line) and on the contralateral side (solid white line) and d) AACID 
difference maps for the same brain post-pre DCA (200 mg/kg) intravenous injection. 
Figure 1.1 Fate of glucose in normal cell under aerobic respiration and in cancer cell 
under aerobic glycolysis. 
Figure 1.2 Basic CEST acquisition scheme (top) shows the low amplitude saturation 
pulse (4s) followed by image acquisition.  The acquisition is repeated for different 
saturation frequencies.  A series of images are produced (middle) representing the object 
at each saturation frequency.  A CEST spectrum is then produced (bottom) for each pixel 
in the image. 
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Figure 3.1 Mouse brain with GBM tumor 15 ±1 days after implantation: a) coronal 
fast spin-echo anatomical image showing regions of interest (ROIs) in the tumor 
(dashed white line) and on the contralateral side (solid white line), b) the 
corresponding baseline AACID map prior to PBS+DMSO intraperitoneal injection, 
and c) the corresponding AACID map two hours post PBS+DMSO intraperitoneal 
injection. 
Figure 3.2 Mouse brain with GBM tumor 15 ±1 days after implantation: a) coronal fast 
spin-echo anatomical image showing regions of interest (ROIs) in the tumor (dashed 
white line) and on the contralateral side (solid white line), b) the corresponding baseline 
AACID map prior to cariporide injection, and c) the corresponding AACID map two 
hours post cariporide (6 mg/kg) intraperitoneal injection. 
Figure 3.3 Mouse brain AACID difference maps for the same brains: a) post PBS+DMSO 
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Figure 3.4 Average AACID value in tumor and contralateral ROIs: a) pre and post 
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mg/kg) intraperitoneal injection (N=6). Error bars represent the standard error of the 
mean. The asterisks indicated p<0.05 in repeated measures t-test. 
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injection c) AACID map post cariporide intraperitoneal injection. 
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Figure 3.7 H&E stained brain section from a representative mouse with U87 glioblastoma 
multiforme (GBM) brain tumor. (a) Whole brain section. (b) Magnified region 
corresponding to the black box in (a) showing the boundary of the tumor within the brain. 
 
 Figure 4.1 Mouse brain with GBM tumor 11 ±1 days after implantation: a) baseline 
AACID map prior to drug injection, b) the AACID map two hours post drug injection, c) 
coronal fast spin-echo anatomical image showing the ROIs in the tumor (dashed white 
line) and on the contralateral side (solid white line), and d) AACID difference maps for 
the same brain post–pre drug injection. 
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Figure 4.2 Mouse brain with GBM tumor 11 ±1 days after implantation: a) baseline 
AACID map prior to drug and glucose injections, b) the AACID map two hours post drug 
and glucose injections, c) coronal fast spin-echo anatomical image showing the ROIs in the 
tumor (dashed white line) and on the contralateral side (solid white line), and d) AACID 
difference maps for the same brain post–pre drug and glucose injections.  
Figure 4.3 Average AACID value in tumor and contralateral ROIs: a) pre and post 
intraperitoneal five drug combination injection (N=6). b) pre and post five drug 
combination + glucose intraperitoneal injection (N=6). Error bars represent the 
standard error of the mean. The asterisks indicated p<0.05 in repeated measures t-
test. 
Figure 4.4 Cleaved Caspase 3 (CC3) Increases in Tumor after Treatment. (A-C) 
Representative images of coronal brain sections of (A) non-tumor control mice, (B) 
mice with U87 tumors, non-treated receiving vehicle only, and (C) mice with tumors, 
treated for eight days with the five drug combination. Blue corresponds to nuclear 
stain (Hoechst), red corresponds to CC3 (apoptotic marker). Scale bar: 0.4 mm. (D) 
Quantification of apoptotic cells in (A-C). ** indicate p<0.01. 
 
xiv 
 
                          List of Abbreviations 
 
MRI      Magnetic Resonance Imaging  
CEST    Chemical Exchange Saturation Transfer  
AACID    Amine Amide Concentration Independent Detection  
CNS      Central Nervous system  
GBM                 Glioblastoma Multiforme  
EGFR                Epidermal Growth Factor Receptor  
VEGF               Vascular Endothelium Growth Factor  
pHi      Intracellular pH  
pHe      Extracellular pH  
ATP                Adenosine Triphosphate   
CA                   Carbonic Anhydrase, Contrast Agent   
AQP                Aquaporin  
CAI                 Carbonic Anhydrase Inhibitor  
DCE- MRI      Dynamic Contrast Enhanced Magnetic Resonance Imaging  
T1                   Longitudinal Relaxation Time  
T2                   Transverse Relaxation Time  
PARACEST       Paramagnetic CEST  
PET                    Positron Emission Tomography   
FDG 
18F FDG                   
Fluorodeoxyglucose 
 Fluorine-18 labeled flurodeoxyglucose 
CT                      Computed Tomography  
MRS                   Magnetic Resonance Spectroscopy   
CR                      Creatine  
LAC                     Lactate  
MT                        Magnetization Transfer  
MTR                     Magnetization Transfer Ratio      
APT 
DMSO 
Amide Proton Transfer  
Dimethyl sulfoxide  
xv 
 
LND 
FSE  
H&E 
MZ               
 Lonidamine 
Fast spin echo 
Hematoxylin and eosin 
Longitudinal magnetization 
µs                         microsecond  
ms      millisecond   
K        Exchange rate   
Kws      Water-solute exchange rate    
Ksw      Solute-water exchange rate  
M                       Moles  
ω      Resonance frequency  
∆ω                       Frequency difference  
R1                       Longitudinal relaxation rate  
RF                      Radio Frequency  
NMR                  Nuclear Magnetic Resonance  
ppm      parts per million  
9.4 T    9.4 Tesla  
B0      The static magnetic field  
TR      Repetition Time  
TE      Echo Time  
ETL      Echo Train Length  
FOV      Field- of- View  
PBS 
PTR  
Phosphate buffered solution 
Proton transfer ratio 
ROI                   
SNR  
Region of interest 
Signal to noise ratio 
WASSR  Water saturation shift referencing 
MTRasym  Asymmetric magnetization 
transfer ratio 
 
1 
 
 
Chapter 1 
1   Endogenous Magnetic Resonance Imaging and Spectroscopy 
Measurements of Intracellular pH in Cancer 
 
 
 
 
 
 
Abstract: 
 Intracellular pH (pHi) plays an important role in the maintenance of normal cell function 
and is maintained within a narrow range by the activity of transporters located at the plasma 
membrane.  A common characteristic of cancer cells is their increased production of acidic 
metabolites and consequently, enhanced acid export to the extracellular space. As a result, cancer 
cells have relatively basic intracellular pH compared to normal cells.  The consequent 
acidification of the extracellular tumor microenvironment supports tumor growth and increases 
metastatic potential. Tumor intracellular pH is an informative indicator of the tumor 
microenvironment as many proteins and peptides have pH-dependent structures and activities.  
In addition, manipulation of tumor pHi can influence proliferation, apoptosis, chemotherapy 
resistance, and thermosensitivity. Therefore, accurate measurement of tumor intracellular pH 
could have many potential applications. The current review summarizes recent advances in 
endogenous MRI methods to measure tumor intracellular pH and summarizes studies that use 
drug treatments to manipulate intracellular pH in cancer. 
 
 
2 
 
 
1. Introduction  
 Elevated intracellular pH in cancer is regulated by several mechanisms that can be 
simultaneously blocked by a combination of drugs leading to acute intracellular acidification.  
The work presented in this thesis applies a technique called chemical exchange saturation 
transfer (CEST) magnetic resonance imaging (MRI) to study intracellular acidification in brain 
tumors after drug injection.  
 This chapter provides an introduction and outline to the presented research on 
intracellular pH measurement in cancer and the drugs that can modulate intracellular pH in 
tumors. Section 1.1 outlines the general organization of the thesis. The regulation of pH in 
normal cells and in cancer cells is presented in Section 1.2. An introduction to CEST theory and 
mechanisms of producing MRI contrast is presented in Section 1.3. Endogenous MRI 
measurement of intracellular pH presented in Section 1.4. Endogenous MRI measurement of 
intracellular pH in cancer is presented in Section 1.5. Finally, a description of various drugs that 
can be used to modulate pH in cancer is presented in Section 1.6. 
 
1.1 Thesis Overview and Objectives  
 
 Anatomical MRI can provide valuable clinical information and enable diagnosis (1-3) in 
many diseases including cancer. MRI can produce excellent soft-tissue contrast with high-
resolution that allows localization and differentiation between different types of soft tissue. 
Advances in the understanding of cell metabolism have modified our understanding of the 
pathophysiology of many diseases (1,2). In this regard, the detection of abnormal physiology 
could help in early disease diagnosis (4,5). Early diagnosis can increase the chance of treatment 
success. Glioblastoma multiforme (GBM) is one of the most aggressive gliomas and deadliest 
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brain tumors, with less than half of patients surviving beyond 12–18 months even with optimal 
treatment (6-9). These tumors represent the second leading cause of death among neurological 
diseases in the United States and present one of the greatest challenges in the treatment of cancer 
in the world (6-9).   
 CEST is a relatively new MRI technique that has emerged to produce contrast related to 
the presence of metabolites and specific proteins.   It can also be made sensitive to biological 
processes such as apoptosis (10) and angiogenesis (11). However, many factors influence CEST 
contrast.  These factors include the concentration of the target (12), temperature (13), and pH 
(14).  In vivo, the pH and temperature are associated with energy producing metabolic efficiency 
(14,15). Recently, many applications of CEST in cancer have focused on measuring intra- and 
extra-cellular pH. Cancer is characterized by significant changes in metabolism resulting in 
changes in pH that are described in detail in Section 1.2. Therefore, measuring pH is a 
potentially valuable marker to indirectly probe metabolic changes in cancer.  
 Positron emission tomography (PET) is the current standard method to image metabolism 
in cancer.  Specifically, the glucose analog called 18F-labeled fluorodeoxyglucose (18F FDG) can 
be detected using PET scanners, and provides a measure of glucose uptake in tumors. Measuring 
tumor uptake of 18F FDG can help in the prediction of tumor response to treatment and is related 
to cancer aggressiveness (16,17). Although PET has much greater detection sensitivity than 
MRI, the development of metabolic imaging by MRI may have some advantages over PET 
because it is easier to interpret when registered to high-resolution anatomical scans, and it is less 
expensive and more accessible(18). Thus, scientists are motivated to develop novel techniques to 
quantify physiological processes using MRI such as tissue acidification, to apply in cancer and 
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stroke. Some metabolic imaging indicators of disease can be used to increase the accuracy of 
diagnosis and prognosis compared to anatomical MR imaging (4,19). 
 
  
1.2 pH Regulation in live tissue  
 
1.2.1 Concept of the pH 
The pH is a logarithmic scale that is used to measure the proton (H+) concentration of a solution. 
The pH concept was first introduced by the Danish chemist Søren Peder Lauritz Sørensen at the 
Carlsberg Laboratory in 1909 (20). A high concentration of protons in solution produces a low 
pH value, and solutions with a low concentration of protons (H+) have a high pH value. There is 
a tendency for water molecules (H2O) naturally to be ionized or dissociate into a hydroxyl ion 
(OH-) and a proton (H+) according to equation (1.1). 
H2O ↔ H+ +OH−                                                                                                     (1.1) 
For example, if an aqueous solution is acidic, the [H+] is higher than [OH−] and if a solution is 
alkaline, the [OH−] is higher than [H+] (21).  The pH value is the negative logarithm of [H+]: 
pH = −log [H+]                                                                                                         (1.2) 
Where the [H+] is the molar concentration of protons in the solution (21).  
1.2.2 pH regulation in normal tissue 
 
Intracellular pH (pHi) is normally maintained within a narrow range by the activity of 
transporters located at the plasma membrane and has an essential role in the maintenance of 
normal cell function. Increases in lactate and proton concentration can cause acidification of the 
tissue microenvironment in many diseases where oxygen supply is less than metabolic demand. 
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The pH value is an essential marker of disease progression, as many proteins, peptides, 
and macromolecules have pH-dependent structures and activities (22,23). Normal pH in both the 
intra-cellular and extra-cellular compartments is maintained through the complex and 
coordinated interaction between several different physiological systems including cellular 
metabolism, the cellular membrane potential, intracellular and extracellular buffering systems, 
cell membrane transporters, delivery of oxygen and glucose, and removal of acid by-products by 
the blood (24). There are many potential pH regulators involved in this process including 
Na+/HCO3– co-transporters, Na+/H+ exchangers, monocarboxylate transporters, the vacuolar 
ATPase, carbonic anhydrase, anion exchangers, the Cl-/HCO3
- exchangers, and ATP synthase 
(25,26). 
A hallmark feature of solid tumors is the maintenance of an alkaline intracellular pH 
(pHi) and an acidic extracellular pH (pHe) (22,27). In normal cells, the pHe is higher (~7.4) than 
the pHi of ~7.0-7.1 (24,28-32).  However, the pH gradient in cancer cells is reversed, with lower 
pHe (~6.7–7.1) than pHi ~7.1-7.3 (24,28-32). This altered pH homeostasis is the consequence of 
increased glycolysis even in the presence of oxygen (aerobic glycolysis), known as the Warburg 
effect (16). The resulting alkaline pHi benefits cancer by supporting increased cell proliferation 
and evasion of apoptosis (22,33) and increases the resistance of the tumor to chemotherapy and 
immunotherapy (34). Glucose metabolism plays an important role in acidification or 
alkalinization of intracellular and extracellular spaces (Figure 1.1). In normal cells, glucose is 
converted to pyruvate, which then enters the mitochondria and oxidized to produce CO2 and H2O 
and ATP (Figure 1.1, left).  In tumor cells, glucose is also converted to pyruvate, but then rapidly 
converted to lactate and H+ in the cytosol (Figure 1.1, right).  The transformation of glucose to 
pyruvate via glycolysis occurs in the cytosol and is described in Equation (1.3). 
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  In the process of the breakdown of one glucose molecule, two nicotinamide adenine 
dinucleotide (NAD+) molecules are reduced to form two NADH.  In addition, phosphorylation of 
two inorganic phosphates (Pi) and adenosine diphosphate (ADP) molecules produces two high-
energy adenosine triphosphate (ATP) molecules.  Two water molecules and two H+ are also 
exported to the extracellular space by transporters located on the cell membrane (22,35). 
Glucose + 2NAD+ + 2ADP + 2Pi →2Pyruvate + 2NADH+ 2H+ + 2ATP + 2 H2O       (1.3) 
 
 
 
 
 
1.2.3 pH regulation in cancer 
 
Intracellular pH (pHi) has an important role in the maintenance of normal cell function 
and is normally maintained within a narrow range by the activity of transporters located at the 
plasma membrane. In cancer, changes in pHi have been correlated with both cell proliferation 
Figure 1.1 Fate of glucose in normal cell under aerobic respiration (left) and in cancer cell 
under aerobic glycolysis (right). 
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and cell death (apoptosis). In cancer tissue, the pH gradient is often reversed. Cancer cells tend to 
undergo the Warburg effect which is the term given to up-regulated glycolysis under aerobic 
conditions (Figure 1.1) (16,22,24,36-40). 
In tumor advancement, cancer cells proliferate and compose large cellular masses, or 
tumors, much faster than adequate vasculature can be produced. Cancer cells in the core of the 
tumor often lack compatible circulation, and the cells that increase glycolysis tend to have an 
advantage (16,22,41). Cancer cells can increase glycolysis using many control mechanisms such 
as increased glucose uptake and up-regulation of pro-glycolytic enzymes such as hexokinase 
(16). The result is an increased population of cancer cells favoring glycolysis. A hallmark feature 
of most cancer cells is increased glucose uptake, which is commonly detected by positron 
emission tomography (PET) using the uptake of the glucose analog 18F-labeled 
fluorodeoxyglucose (18F FDG) (16). Therefore, cancer cells tend to have high rates of glycolysis 
in both aerobic and anaerobic conditions, although anaerobic glycolysis is an inefficient 
respiration pathway to produce ATP compared to the aerobic pathway. Also, cancer cells 
increase the uptake of amino acids for cell proliferation. Therefore, cancer cells increase cellular 
mass by relying on the Warburg effect to meet the energy demand. 
 
A consequence of up-regulated glycolysis in cancer cells is increased amounts of 
pyruvate production leading to increased proton and lactate production (16). Contradictorily, 
there is a tendency for cancer cells to have an alkaline pHi compared to normal cells (22). 
Although the production of lactate by cancer cells is increased, the pHi in cancer cells is more 
alkaline because of increased expression of proton pumps on cellular membranes such as the 
vacuolar ATPase, monocarboxylate transporters MCTs, and Na+/H+ exchangers (22,23). 
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Increased expression of lactate and H+ extruders stimulates glycolysis, which is an important 
energy source for proliferation and increases cancer cell survival. Also, increased efflux of H+ 
and lactate results in increase acidification of the extracellular microenvironment producing a 
lower pHe (~ 6.7–7.1) (24,28-32). Decreased pHe provides selective advantages to cancer cells 
such as increased proliferation and survival of cancer cells because the surrounding normal cells 
cannot survive in the low pH extracellular space. Resultant degradation of normal cells provides 
a significant advantage for evasion and tumor growth (22). Also, the alkaline pHi in cancer cells 
facilitates increased cell proliferation and evasion of apoptosis (22,33) and can decrease the 
efficacy of chemotherapy and immunotherapy (34). Cancer cells produce significantly more 
lactate compared to normal cells (16).  
Inhibition of pyruvate and lactate transporters (MCT) by drugs such as lonidamine and 
quercetin impedes oxidative phosphorylation in cancer leading to energy depletion (42,43). Since 
the metabolism of cancer cells is modulated by increased pHi and decreased pHe, the 
measurement of pHi and pHe may improve the reliability of the diagnosis and staging of disease  
advancement in tumors. Many anti-cancer agents have intracellular and extracellular pH-
dependent activity and pharmacokinetics. Also, the measurement of pH change has been used to 
predict tumor response to chemotherapy and radiation therapy (8,25,44). Therefore pH 
measurement could help to increase the efficacy of chemotherapy and improve cancer treatment 
plans (24,45). 
 Chemotherapy agents preferentially cross the cell membrane when passing through the 
acidic extracellular environment in cancer tissue. Upon entrance to the basic intracellular 
space of cancer cells, the weakly acidic agents are trapped by ionization. Previous experimental 
results support the use of weakly acidic chemotherapy agents when the pH balance is altered in 
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cancer (24,45). In addition, tumor intracellular acidification could decrease resistance of the 
tumor to weakly basic drugs such as Doxorubicin and trigger apoptosis in cancer cells (46-49). 
 
 
1.3 General Overview of CEST contrast 
 
 CEST represents a relatively new class of MRI contrast that developed from the field of 
NMR spectroscopy (50). Consider two separate pools of 1H nuclei in the system being measured 
inside the static magnetic field (B0) of the MRI scanner.  One pool is the bulk water resonating at 
the Larmor frequency, the second pool is a smaller solute pool resonating at a different 
frequency.  A low-power radiofrequency pulse is applied at the specific MR frequency of the 
solute (S) proton pool. Over time, this radiofrequency pulse will equalize the number of nuclei in 
the high energy and low energy states.  This condition is known as saturation of solute proton 
pool. The protons are the solute pool undergo chemical exchange with protons in the bulk water 
(W) pool. There is a net transfer of high energy protons to the bulk water proton pool through the 
process of chemical exchange, effectively decreasing the population difference between the low 
energy and high energy states. This reduces the net magnetization of the water pool leading to 
decreased MR image intensity when detecting the bulk water signal. This chemical exchange 
process amplifies the detected signal change caused by the low concentration solute. Using 
standard MRI acquisition methods, the images can be formed from the bulk water magnetization. 
 To create a CEST spectrum, a radiofrequency saturation pulse is repeatedly applied over 
a range of frequencies (51) (Figure 1.2). The amplitude of the bulk water signal following 
application of the saturation pulse is plotted as a function of the saturation frequency (Figure 
1.2).  The CEST spectrum is usually referenced to the frequency of bulk water at 0 ppm.  Direct 
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saturation of water at 0 ppm causes a large decrease in the bulk water signal observed in the 
CEST spetrum at this frequency. Importantly, the CEST effect produced by the exchange of 
solute pool protons with bulk water protons causes a decrease in the bulk water signal measured 
at saturation frequencies other than 0 ppm. The change in the CEST signal at these specific 
frequencies is used as the measurement of the CEST effect. There are several parameters can be 
used to characterize the CEST effect such as the magnitude of the change in water saturation 
amplitude and the CEST peak width (52-55). The CEST spectrum corresponding to normal 
mouse brain shows clear CEST peaks at 2.0 ppm and 3.5 ppm (Figure 1.3). 
 
 
 
 
 
Figure 1.2 Basic CEST acquisition scheme (top) shows the low amplitude saturation pulse 
(4s) followed by image acquisition.  The acquisition is repeated for different saturation 
frequencies.  A series of images are produced (middle) representing the object at each 
saturation frequency.  A CEST spectrum is then produced (bottom) for each pixel in the 
image.  
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1.4 Chemical Exchange Saturation Transfer  
 To describe the production of CEST contrast, consider the Larmor frequency of protons 
0 in a main magnetic field B0 given by Equation 1.4 where 0 is in rad s-1, B0 is in Tesla and  is 
the gyromagnetic ratio in radians per second Tesla (106 rad s-1 T-1). 
0 =                                                                                                                                                                               (1.4) 
 The Larmor frequency of the bulk water protons in our two pool system is set as the 
reference frequency 0 for the CEST experiment. The frequency offset or chemical shift of the 
solute protons () from the bulk water protons is defined in ppm according to Equation 1.5. 
=
𝑠−0
0
× 106                                                                                                   () 
 In a typical CEST experiment, solute protons resonating at a frequency that is chemically 
shifted () from the bulk water protons are saturated using an RF pulse. Therefore, the 
Figure 1.3 Normal mouse brain: a) coronal fast spin-echo anatomical image showing a 
manually defined region of interest (sold white line), b) the CEST spectrum corresponding 
to the tissue within the ROI shows visible CEST effects at 2 ppm and 3.5 ppm.  
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application of an RF pulse of magnitude B1 at the frequency offset of the solute protons leads to 
the excitation of protons in this pool from a lower energy state to higher energy state. The 
saturation of the solute pool is achieved using RF pulses when the number of protons at each 
energy level is equal. The process of chemical exchange occurs when a nucleus freely transfers 
between two different pools that have environments that are chemically different. For CEST 
applications and experiments, the most common pathways of chemical exchange include 
molecular exchange, proton exchange, or a combination of both pathways. An example of proton 
exchange is when a proton an amine group (solute pool) within a specific protein moves to the 
bulk water pool (H2O). The molecular exchange is more commonly associated with CEST 
contrast agents, when for example a water molecule moves from the bulk water pool to an agent 
bound pool. The chemical exchange must occur on the slow-to intermediate regime on NMR 
timescale to produce observable CEST contrast.  This is defined by Equation 1.6.  
s ≥ Ksw                                                                                                                       (1.6) 
 Where s is the frequency offset between the solute and bulk water protons and Ksw 
represents the chemical exchange rate from the solute to the bulk water pool. The chemical shift 
 is the frequency offset s normalized by the reference frequency 0. The chemical exchange 
rate Ksw depends on pH and temperature for a specific sample at a fixed concentration of solute. 
During a long RF saturation pulse (e.g. saturation for several seconds), through the process of 
chemical exchange, protons from the solute pool will move to the bulk water pool.  Since the 
solute pool protons are saturated, there is a net transfer of high energy protons to the bulk water 
pool causing an increase in a number of protons antiparallel with B0 (high energy protons) in this 
pool (partial saturation).  This reduces the net magnetization of the bulk water pool leading to a 
reduction in the recorded signal.  During the saturation pulse, as chemical exchange decreases 
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the net magnetization of the bulk water pool (Mzw), the longitudinal relaxation of bulk water 
protons restores the net magnetization.  This competing process limits the achievable saturation 
of the bulk water pool and over the duration of the saturation pulse leads the system to a steady 
state condition. The observed CEST effect is the resulting partial saturation of the bulk water 
proton pool due to saturation of the solute proton pool. The proton transfer ratio (PTR) (56) can 
be used to quantify the CEST effect by measuring the reduced bulk water magnetization at 
steady state 𝑀𝑧𝑤
𝑠𝑠  relative to the equilibrium magnetization 𝑀𝑧𝑤
0  as shown by: 
PTR = 1 −
𝑀𝑧𝑤
𝑠𝑠
𝑀𝑧𝑤
0                                                                                 (1.7)           
 The reduction in the bulk water MRI signal caused by the saturation of the smaller solute 
pool and exchange the solute protons with bulk water protons is known as CEST contrast. CEST 
acts as an amplification mechanism due to the accumulation of bulk water saturated protons over 
the duration of a long RF saturation pulse.  
 
1.4.1 The CEST Spectrum 
 To create a CEST spectrum (Figure 1.2) the MRI signal from bulk water at steady state 
𝑀𝑧𝑤
𝑠𝑠  is normalized to the equilibrium magnetization 𝑀𝑧𝑤
0  (𝑀𝑧𝑤
𝑠𝑠  /𝑀𝑧𝑤
0 ) and plotted as function of 
the RF saturation pulse frequency offset (chemical shift from bulk water set to 0 ppm). The MRI 
signal is obtained from a series of MR images acquired after the radiofrequency pulse is applied 
at each different saturation frequency. A CEST peak can be visualized in the CEST spectrum as 
a reduction in the intensity of the MRI signal if suitable experimental parameters are applied 
(e.g. RF amplitude). 
 There are many factors that can influence CEST contrast such as: concentration of the 
metabolites, pH, temperature, B0 homogeneity, B1 homogeneity, and T1 relaxation time. The 
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amide-proton transfer contrast typically used to measure intracellular pH can be obtained 
optimally by using a low power and long irradiation pulse. While CEST contrast from the faster 
exchanging amine proton can be maximized using a higher power and a shorter irradiation pulse 
(57,58).  
 
1.4.2 Factors that Modulate CEST Contrast 
 One limitation of CEST imaging is the requirement of homogeneous magnetic fields (B0 
and B1) to ensure consistent RF irradiation across the entire sample. Differences in B0 field 
within the sample lead to shifts in the CEST spectrum.  Fortunately, these shifts can be corrected 
on a pixel-by-pixel basis using a separately acquired CEST spectrum and measuring the 
chemical shift of the on-resonance CEST saturation of water.  This water saturation shift 
referencing (WASSR) approach has been used extensively (59), to account for B0 variation.  
Variations in RF transmit B1 homogeneity are more difficult to correct and require careful 
calibration of the CEST effect with B1 along with B1 mapping (60,61).  A better approach is to 
avoid the need to for correction by ensuring a homogeneous B1 field is produced within the 
sample of interest.  B1 mapping is required to verify that the B1 field is homogeneous and to 
avoid introducing B1 corrections of the measured CEST effect. 
 
1.5 Endogenous MRI Measurement of Intracellular pH 
 
 Although pH is an important parameter within the tissue microenvironment that impacts 
numerous cellular processes and protein behavior, the measurement of in vivo intracellular pH 
has been limited to only two methods: 31P MR spectroscopy and CEST. 
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1.5.1  31P 
 The phosphorous nucleus (31P) is detectable by nuclear magnetic resonance (NMR) and is 
also 100% naturally abundant. The sensitivity of 31P is 6.63% that of 1H total sensitivity because 
the strength of a nuclear signal is proportional to γ³, where γ is the gyromagnetic ratio. The 31P  
and the 1H have gyromagnetic ratio 17.24 MHz/T and 42.58 MHz/T respectively. Most 
phosphorous containing metabolites within cells have concentrations between 0.1 mM and 10 
mM. The most important NMR signals from endogenous 31P within tissues arise from inorganic 
phosphate (Pi), adenosine triphosphate (ATP), and phosphocreatine (PCr). From the chemical 
shift difference between the Pi and PCr peaks, the intracellular pH of mammalian tissues can be 
measured accurately and non-invasively (28). The intracellular concentration of Pi is 2–3 mM, 
but the extracellular concentration of Pi is only 1.0 mM. Therefore the measured chemical shift 
of Pi reflects predominantly the intracellular pH of tissue. There are many cellular processes 
such as necrosis that can increase the extracellular inorganic phosphate. Therefore these 
processes can complicate intracellular pH measurement using 31P MRS (62). 
  31P MRS has been used to study in vivo pHi for many years (28,29,32,63-68).  However, 
because of the low sensitivity of the 31P nucleus, to make reliable pHi measurements using
 31P 
MRS requires long scan times and the use of large voxels. However, the technique has been 
highly valuable for monitoring changes in high-energy phosphates, Pi, and pH under hypoxic 
and ischemic conditions (69-73). 31P MRS has also been used to study brain tumors (74), 
showing that the intracellular pH is alkaline and not acidic as previously thought and that the 
intracellular pH of tumors is higher than that of normal tissue (75).  
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1.5.2 Chemical Exchange Saturation transfer (CEST) 
 
 CEST contrast has been used to measure tissue pH, based on the CEST effect observed 
from amide and amine protons that resonate at chemical shifts of 3.5 ppm and 2.75 ppm 
respectively downfield from bulk water [33]. The amide protons visible at 3.5 ppm are associated 
with mobile proteins and peptides. Approximately 90% of proteins and peptides originate from 
the intracellular compartment, and consequently, pH measured using amide and amine proton 
CEST effects is heavily weighted to the intracellular space and is referred to as intracellular pH 
(14,58,76,77).  Intracellular pH measurement using amide proton transfer (APT) imaging was 
first developed by Zhou et al. but the method proposed had several limitations [33]. They used 
the asymmetric magnetization transfer ratio (MTRasym) to reduce the effect of macromolecule 
magnetization transfer (MT) effects from the CEST contrast using Equation 1.8. 
MTRasym() =
Mz(−)−Mz()
Mz(−)
                                                                              (1.8) 
where MZ(Δω) represents the bulk water magnetization after saturation at the frequency 
offset Δ and MZ(-Δω) represents the bulk water magnetization after saturation at the frequency 
offset -Δ Quantitative pH measurement using APT imaging is susceptible to error because the 
amide proton transfer ratio (APTR) is also affected by cellular water content, longitudinal 
relaxation, and amide proton concentration. Also, nuclear Overhauser effects (NOEs), which are 
observed between -2.0 and -4.0 ppm, can affect the MTRasym measurement as NOEs are directly 
opposite the amide protons at 3.5 ppm. Several other CEST measurements are also sensitive to 
pH.  For example, amine protons associated with glutamate (58,78,79) also have exchange rates 
sensitive to intracellular pH (12,80). Similarly, the hydroxyl protons associated with glucoCEST 
measurements have exchange rates that are pH dependent (18,81-84). However, these hydroxyl 
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protons and the amine protons associated with glutamate are also affected by changes in 
longitudinal relaxation and the concentration of protons limiting their use for measuring absolute 
pH in vivo. 
 
 Another CEST based method to measure intracellular pH was developed by our group 
called amine and amide concentration-independent detection (AACID).  This technique uses the 
ratio of the CEST effects from the 3.5 ppm amide protons and the 2.75 ppm amine protons to 
produce pHi dependent contrast.  Using B0-corrected (166) and smoothed CEST spectra, AACID 
values were measured on a voxel-by-voxel basis. AACID represents the ratio of the CEST 
effects of the amine protons resonating at 2.75 ppm and the amide protons at 3.50 ppm, 
normalized by magnetization transfer (MT) effects measured after saturation at 6.0 ppm.  
AACID was calculated using equation (1.9) (60).   
 𝐴𝐴𝐶𝐼𝐷 =
𝑀𝑍3.5 𝑝𝑝𝑚×(𝑀𝑍6.0 𝑝𝑝𝑚−𝑀𝑍2.75 𝑝𝑝𝑚)
𝑀𝑍2.75 𝑝𝑝𝑚×(𝑀𝑍6.0 𝑝𝑝𝑚−𝑀𝑍3.5 𝑝𝑝𝑚)
     (1.9) 
 
This approach was shown to be independent of tissue macromolecule concentration, tissue 
temperature, and bulk water T1 relaxation (60).  Importantly, the B1 amplitude of the saturation 
pulse is set at an intermediate level to provide sensitivity to both amine and amide protons.  
McVicar et al. (85) used AACID-CEST MRI to evaluate the sensitivity of pHi for the detection 
of changes in tumor pHi induced by a single dose of lonidamine (LND) the monocarboxylate 
transport inhibitor. Similarly, Marathe et al. (86) demonstrated that a single dose of topiramate, a 
carbonic anhydrase inhibitor, could induce intracellular acidification in GBM tumors.  The focus 
of this thesis is to identify and evaluate drugs that could inhibit other pHi-regulators and 
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glycolytic enzymes that modulate pHi since pH modulation by a single agent will likely be 
compensated by other mechanisms over time. 
 
1.6 Endogenous MRI Measurement of Intracellular pH in Cancer 
 
 The measurements of intracellular pH changes have been used to evaluate tumor response 
to treatments such as chemotherapy and radiation therapy (25,44,87). An initial study using 31P 
measurement of intracellular pH in brain tumors (74) showed that the intracellular pH of the 
tumor was alkaline, not acidic. In a different study, it was also found that the intracellular pH of 
untreated tumors was higher than the intracellular pH of normal tissue (75). Ben-Yoseph et al. 
also used 31P MRS to measure tumor pHi after drug treatment and found a decreased of 0.45 pH 
units after injection of 100 mg/kg lonidamine (87). Unfortunately, as described earlier, there are 
many limitations associated with the use of 31P to measure pHi. Therefore, work in our laboratory 
has focused on the use of a CEST technique called AACID to quantify the rapid and measurable 
in vivo tumor acidification after drug injection (85,86,88,89). 
 
1.7 Drugs to modulate pH in cancer: 
 
 Cancer cells consume a large amount of glucose, and convert majority of glucose to 
pyruvate even in the presence of oxygen, a phenomenon known as “aerobic glycolysis” or the 
“Warburg Effect” (90). Although the Warburg effect leads to higher metabolic acid production, 
cancer cells also adaptively increase the expression of regulators that extrude lactate and protons 
that would otherwise accumulate producing a relatively alkaline pHi and consequently increased 
pyruvate production in the cytoplasm compared to normal cells (91). A hallmark feature of solid 
19 
 
 
tumors is an alkaline intracellular pH (pHi) and an acidic extracellular pH (pHe) (22,27). 
Extracellular acidosis is a hallmark feature of cancer and is an important factor that drives 
malignant progression and increases metastatic potential and treatment resistance (16,92-97). 
 The regulation of pH in the intra- and extra-cellular compartments of the tumor is a 
complex integration of many processes.  These pH regulators include Na+/H+ exchangers, 
monocarboxylate transporters, the vacuolar ATPase, carbonic anhydrase, anion exchangers, the 
Cl-/HCO3
- exchangers, Na+/HCO3– co-transporters, and ATP synthase (25,26). Maintaining an 
alkaline intracellular pH benefits the cancer cell making it less likely to initiate apoptosis and 
enhancing cell proliferation (22,33).  An alkaline intracellular pH can also increase the resistance 
of cancer to chemotherapy and immunotherapy (34,40,98-100). Inhibition of pyruvate and lactate 
transporters (MCT) with drugs such as lonidamine and quercetin impedes oxidative 
phosphorylation in cancer leading to energy depletion (42,43,101). Since cancer cells produce 
significantly more lactate compared to normal cells (16,94,102,103), the basic pH of the 
intracellular compartment is maintained by moving lactate and other acid metabolites to the 
extracellular space.  This causes acidification of the extracellular microenvironment and 
effectively reverses the intracellular / extracellular pH gradient compared to healthy cells (104-
109). 
 There are many drugs that are capable of interfering with pH regulation in cancer cells. 
As mentioned above, using 31P MRS Ben-Yoseph et al. showed that injection of lonidamine at a 
dose of 50 mg/kg decreased tumor pHi by 0.25 while a dose of 100 mg/kg decreased tumor pHi 
by 0.45 pH units (87). Using AACID-CEST MRI our group also found that a single dose of 
lonidamine (100 mg/kg) decreased tumor pHi by 0.45 (85), and that a single dose of topiramate 
(120 mg/kg) decreased pH by 0.17 (86).  The objective of this thesis was to explore the 
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intracellular acidification efficacy of other drugs and drug combinations. It is important to 
identify additional drugs that could inhibit other regulators of pHi to modulate pHi since the 
effect of a single pharmacologic agent that modulates intracellular pH will likely be compensated 
by other mechanisms over time.  In the following paragraphs, a number of different potential 
drugs are described that target the most common pH regulatory mechanisms in cancer cells.  In 
all cases, the drugs described are approved for use in humans.   
 Na+/H+ exchange inhibitors (e.g. NHE1) play a significant role in maintaining the acidic 
pHe and alkaline pHi in malignant tumors, and regulating cell volume (110).  Amiloride and 
cariporide are Na+/H+ exchange inhibitors. They have been used to decrease intracellular pH in 
glioblastoma cells in vitro. Amiloride was able to reduce intracellular pH in U87 GBM cells 
from 7.37 to 7.05 within 50 min (111). Also, cariporide decreased pHi by 0.3-0.5 pH units within 
2 hours in glioblastoma cells when measured by BCECF, AM (2',7'-Bis-(2-Carboxyethyl)-5-
(and-6)-Carboxyfluorescein, Acetoxymethyl Ester) in vitro (111).  
 Quercetin is a natural plant product that has been used as an effective chemotherapeutic 
agent to treat many cancer types such as breast cancer and brain cancer.  Quercetin can be given 
orally and is safe over a wide range of doses (94,112,113). Quercetin is an inhibitor of 
monocarboxylate transporters (MCTs) (94,114-117), and has also been characterized as an 
MCT1 and MCT2 specific inhibitor (114). Quercetin produces intracellular acidification in 
tumors by inhibiting lactate transport (94,114-117). In addition, quercetin enhances the 
efficiency of chemotherapy, suppresses human glioblastoma cell survival by increasing caspase-
3 activation, and induces cell apoptosis in glioblastoma and many other types of cancer cells in 
vitro (118-124). Quercetin is more potent and effective in an acidic tumor microenvironment 
(125-127).  
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 Acetazolamide induces intracellular acidification by inhibiting carbonic anhydrase 
activity and decreasing the expression of the aquaporin-1 (AQP1) (128-136) water channel. 
Acetazolamide has also been shown to inhibit angiogenesis and endothelial cell proliferation in 
lung and breast tumor in animal models and human glioblastoma cells (137-140).  
 Pantoprazole (PPZ) is a proton pump inhibitor (PPI) and induces cancer cell death by 
inhibiting the V-ATPase.  PPIs are considered to have anti-tumor effects due to their ability to 
induce tumor cell death by reversing H+ homeostasis in the tumor microenvironment by 
inhibiting the V-ATPase.  Pantoprazole has also been shown to be a cancer agent and is effective 
against many types of cancer cells (141). PPZ can be given alone or concurrent with 
chemotherapy such as doxorubicin.  After PPZ treatment, apoptotic cell death was observed 
selectively in cancer cells (142,143). Several PPIs (omeprazole, esomeprazole, and pantoprazole) 
raise lysosomal pH and decrease intracellular pH, a feature associated with their ability to 
sensitize cancer cells to chemotherapeutics (105). Agents that alter tumor pH homeostasis can 
decrease drug resistance and inhibit tumor growth (99,144-153). 
 Dichloroacetate (DCA) is an anti cancer agent.  DCA can decrease the expression of 
monocarboxylate transporters and V-ATPases. It was used as a cancer treatment in two human 
hepatoma (HCC-LM3 and SMMC-7721) cell lines (154). In addition, DCA has been shown to 
induce cell death in cancer cell lines including from breast, prostate, lung, medullary thyroid, and 
endometrial cancers, as well as myeloma and glioblastoma multiforme (47,154,155). 
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1.8 Thesis Overview: 
 Cancer cells have evolved a high dependence on glycolysis due to the Warburg effect. 
The overall goal of this thesis is to determine whether different drugs that block various pH 
regulatory mechanisms can acidify brain tumors and to measure the magnitude of tumor 
acidification using CEST MRI.  In this thesis, specific drugs are used to induce intracellular 
acidification (lowering pHi) in brain tumors in an attempt to induce a measurable physiologic 
response.  The response of the tumor to each drug could be used to stage the cancer, define the 
boundary of the tumor, or predict treatment response.   The effect of the drug on tumor pH is 
measured by CEST MRI in vivo using a mouse model of brain cancer. Chapter 2 describes the 
results obtained when using the drug dichloroacetate (DCA), which is approved for human use, 
to induce intracellular acidification in glioblastoma.  This study is the first to show decreased 
intracellular pH after DCA injection. In chapter 3, the drug cariporide is used to decrease 
Figure 1.4 pH control systems in cancer and normal cells. intracellular alkalinisation is a key 
factor in cancer cells for cells transformation. pH-gradient is reversed in cancer cells 
compared to the normal cells. Na+/H+, MCT (monocarboxylate transporter), CA (carbonic 
anhydrase) and V-ATPase (vacuolar-ATPase) are the most important transporters and the 
exchangers that cause intracellular alkalinisation of the cancer cells. 
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intracellular pH in a mouse model of glioblastoma. Cariporide is a Na+/H+ exchange inhibitor. 
Chapter 4, we tested the hypothesis that combined treatment with five drugs that block different 
pH regulatory mechanisms have a greater effect on tumor acidification than any single drug. We 
also tested the hypothesis that providing glucose as an energy substrate to the tumor would 
increase the intracellular acidification.  The final chapter of the thesis, summarizes all results 
obtained and provides a framework to translate this work into humans and to continue further 
testing of tumor acidification as a treatment strategy, optimized using CEST MRI. 
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Abstract: 
Intracellular pH (pHi) plays an important role in the maintenance of normal cell function, and is 
maintained within a narrow range by the activity of transporters located at the plasma membrane. 
Modulation of tumor pHi may influence proliferation, apoptosis, chemotherapy resistance, and 
thermosensitivity. Chemical exchange saturation transfer (CEST) is a novel MRI contrast 
mechanism that is dependent on cellular pH. Amine and amide concentration-independent 
detection (AACID) is a recently developed CEST contrast method that is intracellular pH (pHi) 
weighted.  Dichloroacetate (DCA) can alter tumor pHi by inhibiting the enzyme pyruvate 
dehydrogenase kinase causing reduced lactate (increasing pHi), or by decreasing the expression 
of monocarboxylate transporters and vacuolar ATPase leading to reduced pHi.  Since the net in 
vivo effect of DCA on pHi is difficult to predict, the purpose of this study was to quantify the 
magnitude of acute pHi change in glioblastoma after a single DCA injection using AACID CEST 
MRI. Using a 9.4T MRI scanner, CEST spectra were acquired in six mice approximately 14 days 
after implanting 105 U87 human glioblastoma multiforme (GBM) cells in the brain, before and 
after intravenous injection of DCA (dose: 200 mg/kg). Three additional mice received only 
25 
 
 
phosphate buffered saline (PBS) injection and were studied as controls. Repeated measures t-test 
was used to compare AACID changes in tumor and contralateral tissue regions of interest. One 
hour after DCA injection there was a significant increase in tumor AACID level by 0.04±0.01 
corresponding to a 0.16 decrease in pHi, and no change in AACID in contralateral tissue. 
Inspection of AACID maps following PBS injection showed no differences. The use of DCA to 
induce a tumor specific pH change detectable by AACID CEST MRI is consistent with previous 
studies that have shown similar effects for lonidamine and topiramate. This study demonstrates 
that a single dose of DCA can be used as a pharmacological challenge to induced rapid tumor 
intracellular acidification. 
2.1 Introduction 
Gliomas are the most common primary brain tumors of the central nervous system (CNS). 
Glioblastoma multiforme (GBM) is one of the most aggressive gliomas and deadliest brain 
tumors, with less than half of patients surviving beyond 12-18 months even with optimal 
treatment (6-8,156). These tumors represent the second leading cause of death among 
neurological diseases in the United States and present one of the greatest challenges in the 
treatment of cancer in the world (6-9). The current standard of care of GBM tumors includes 
surgical resection of the primary tumor followed by aggressive concurrent radiation and 
chemotherapy (157). However, over 90% of GBM tumors recur due to migratory cancer cells 
that avoid treatment (9).  
 
              In normal cells, the extracellular pH (pHe) is ~7.4, which is higher than the intracellular 
pH (pHi) of ~ 7.0-7.1 (24,28-32) .  A emerging hallmark feature of malignant solid tumors is 
deregulation of energy metabolism (90) producing an alkaline pHi and acidic pHe; the 
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intracellular/extracellular pH gradient in cancer cells is reversed such that the pHe is ~6.7–7.1 
and pHi is ~ 7.1-7.3 (24,28-32). This pH gradient reversal is primarily due to the use of aerobic 
glycolysis by cancer cells for energy production even in the presence of oxygen, known as the 
Warburg effect (16). Although the Warburg effect leads to higher metabolic acid production, 
cancer cells also adaptively increase the expression of regulators that extrude lactate and protons 
producing a relatively alkaline pHi (91). These regulators include Na
+/HCO3
– co-transporters, 
Na+/H+ exchangers, monocarboxylate transporters, the vacuolar ATPase, and carbonic 
anhydrases (25,26). Increased pHi in cancer promotes proliferation and evasion of apoptosis (22). 
Conversely, decreasing pHi in cell culture models has been shown to enhance the effectiveness 
of hyperthermia, radiation, and chemotherapy treatments in a variety of cancer cell lines 
(26,33,48,49,158). 
 
However, the response of tumor cell cultures does not necessarily predict the behavior of 
solid tumors in vivo. Until recently, the study of in vivo intracellular pH was performed by 
phosphorus (31P) magnetic resonance spectroscopy (63). However, 31P MRS measurements are 
limited by low sensitivity, requiring the use of large voxels and/or long scan times to make 
reliable pHi measurements. More recently, the use of endogenous chemical exchange saturation 
transfer (CEST) magnetic resonance imaging (MRI) has been shown to be sensitive to 
intracellular pH (58,60). One specific CEST based method called amine and amide 
concentration-independent detection (AACID) uses the ratio of CEST effects from the 3.5 ppm 
amide protons and the 2.75 ppm amine protons to produce pHi dependent contrast that is 
independent of tissue macromolecule concentration, tissue temperature, and bulk water T1 
relaxation (60). The CEST contrast originates from exchangeable amine and amide protons that 
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are found in tissue proteins and peptides (14,58,77,159).  However the AACID CEST 
measurement of tissue pH is highly weighted to the intracellular compartment (14) because 
almost 90% of total protein content exists in the intracellular space (77).  McVicar et. al. (85), 
used AACID-CEST MRI to evaluate the sensitivity of pHi-dependent CEST contrast for the 
detection of changes in tumor pHi induced by a single dose of the monocarboxylate transport 
inhibitor lonidamine (LND). Similarly, Marathe et. al. (86) demonstrated GBM specific 
intracellular acidification following a single dose of the carbonic anhydrase inhibitor topiramate. 
Dichloroacetate (DCA) is a small molecule that is orally available for use in humans 
(160,161), has low toxicity compared to other agents (155), and has been shown to induce cell 
death in several different types of cancer (160,161).  Preclinical work using DCA shows 
effectiveness as a cancer treatment to induce cell death in different types of tumors.  For 
example, it was used as a cancer treatment in two human hepatoma (HCC-LM3 and SMMC-
7721) cell lines (154). In addition, DCA induces cell death in cancer cell lines from breast, 
prostate, lung, medullary thyroid, and endometrial cancers, as well as myeloma and glioblastoma 
multiforme (47,154,155). However there are no ongoing clinical trials involving the use of DCA 
to treat glioblastoma (clinicaltrials.gov). The effect of DCA on intracellular pH is difficult to 
predict.  DCA inhibits pyruvate dehydrogenase kinases (PDKs), which reverses the Warburg 
effect by activating pyruvate dehydrogenase (PDH) and redirecting pyruvate back into the 
mitochondria (160,162). This metabolic change is expected to increase intracellular pH by 
reducing the production of lactate. However, cancer cells also have a higher expression of 
monocarboxylate transporters and V-ATPases compared to normal cells.  Since DCA acts to 
decrease the expression of these transporters (163) it is expected to have a more pronounced 
effect in cancer cells compared to normal cells leading to reduced pHi in tumors. Therefore, it is 
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unclear whether a single dose of DCA would cause a net increase or decrease in pHi. The goal of 
the current study was to measure the magnitude of GBM tumor intracellular pH change induced 
by a single dose of DCA. The change in pHi was measured by AACID CEST MRI. We 
hypothesize that a single dose of DCA will not alter pHi within contralateral tissue, but will cause 
intracellular acidification within tumor regions within one hour of treatment because the effect of 
DCA on MCTs and V-ATPases dominates. The combination of DCA treatment and CEST MR 
imaging may provide a novel method to detect GBM tumors. The targeting of tumor metabolism 
is also potentially a cancer treatment strategy (47,160) and could change the tumor 
microenvironment to enhance concurrent anti-cancer treatment. 
2.2 Experimental 
2.2.1 Subjects 
Nine mice were included in the current study. Six NU/NU mice with U87MG brain tumors were 
used to evaluate the effect of injecting 200 mg/kg of DCA. Three NU/NU mice with U87MG 
brain tumors were used as control. Control mice received intravenous phosphate buffered saline 
(PBS) injection only. All animal procedures were performed according to a protocol that was 
consistent with guidelines established by the Canadian Council on Animal Care and was 
approved by the University of Western Ontario Animal Use Subcommittee. 
2.2.2 Dichloroacetate 
Sodium dichloroacetate (DCA) with linear formula (Cl2CHCO2Na) was purchased from Sigma –
Aldrich (Canada). The drug was dissolved in PBS (30 mg/mL). DCA was administered 
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intravenously through a tail vein catheter to achieve a dose of 200 mg/kg over the course of 1 
min as previously described (46,164). 
2.2.3 Animal tumor preparation 
GBM brain tumors were induced in 22-27g, NU/NU mice (N=6) using U87MG glioma cells 
established from a human GBM (ATCC; Rockville, MD, USA) as described previously 
(165). Briefly, U87MG cells were grown in Dulbecco’s modified Eagles’s medium 
supplemented with 10% fetal bovine serum (Wisent Inc., St-Jean-Baptiste, QC, Canada) at 37oC 
in a humidified incubator with 5% CO2 and passaged twice a week. On the day of injection, 
U87MG cells were washed and dissociated with versene solution (phosphate-buffered saline 
(PBS) plus 0.5 mM EDTA), then washed twice with PBS, counted and re-suspended to a final 
concentration of 1 x 105 cells in 2 μl PBS.  Prior to injection, mice were anesthetized by 
inhalation of 4% isoflurane and maintained using 1.5% isoflurane mixed with 100% oxygen. The 
mouse was placed in a stereotactic head frame (Stoelting instruments, Wood Dale, IL, 
USA).  The scalp was swabbed with betadine and an incision was made in the scalp to expose 
the bregma.  A 1 mm diameter hole was drilled at coordinates measured from the bregma (1 mm 
anterior and 2 mm lateral). U87MG cells (2 μl) were injected at a rate of 0.5 l/min, at a position 
3 mm deep from the bregma into the right frontal lobe using a Hamilton (Reno, NV, USA) 
syringe with a 27-gauge needle attached. 
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2.2.4 General mouse preparation for in vivo imaging 
Approximately 15 ±1 days after cancer cell injection, the mice were scanned on a 9.4 T small 
animal MRI equipped with a 30 mm millipede volume coil (Agilent, Santa Clara, CA, USA). 
Anesthesia was induced using 4% isoflurane in oxygen and maintained with 1.5%–2.5% 
isoflurane in 100% oxygen. The mouse was secured on a custom-built MRI-compatible stage and 
the head was secured using a bite bar (86) and surgical tape to limit motion due to respiration. 
Temperature was monitored with a rectal temperature probe. Body temperature was maintained 
at 36.9-37.1oC throughout imaging by blowing warm air over the animal using a model 1025 
small-animal monitoring and gating system (SA Instruments Inc., Stony Brook, NY, USA). To 
ensure animals were free breathing throughout the study, respiration was also monitored with a 
respiratory sensor pad connected to a pressure transducer that was placed on the thoracic region.  
Following pre-injection imaging, the mouse was injected with DCA inside the MRI by delivering 
the drug through a fine plastic tube ended with a needle inserted into the animal tail vein. 
Animals were sacrificed immediately after MR imaging. 
2.2.5 In vivo Magnetic Resonance Imaging 
Standard anatomical T2-weighted images were used for tumor detection. The T2-weighted 
images were acquired using a 2-dimensional coronal fast spin echo pulse sequence (FSE) with 
parameters: TR/TE = 3000/10 ms, ETL = 4, effective TE = 40 ms, FOV = 25.6 x 25.6 mm2, 
matrix size = 128 x 128, slice thickness= 1 mm, acquisition time ≈ 3 minutes. Following initial 
tumor detection, the two slices from the T2-weighted images with the greatest tumor coverage 
(representing a total thickness of 2 mm) were selected and the coordinates used to position the 
coronal CEST image. CEST images were acquired using a fast spin-echo (FSE) pulse sequence 
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(TR/TE = 7000/7 ms, ETL = 32, effective TE = 7 ms, FOV = 25.6 x 25.6 mm2, matrix size = 64 
x 64, slice thickness = 2 mm, acquisition time ≈ 18 minutes) preceded by a continuous wave 
radiofrequency (RF) pulse with amplitude 1.5-µT and 4s duration. The CEST images were 
acquired at different saturation frequencies (from 1.2 to 4.5 (∆=0.1) ppm, from 5.4 to 6.6 (∆=0.1) 
ppm, and -1000 and 1000 ppm images were acquired as references, total 49 images). A complete 
series of CEST images were acquired three times before and three times after drug injection to 
improve signal-to-noise ratio. For B0 correction, the water saturation shift referencing (WASSR) 
technique was used (166). A linearly spaced 37-point WASSR CEST spectrum (acquisition time 
≈ 9 minutes) with saturation frequencies ranging from -0.6 – 0.6 ppm was acquired using the 
same pulse sequence except preceded by a short (100 ms) low amplitude (0.2 µT) RF saturation 
pulse. Each WASSR spectrum (166) and CEST spectrum was interpolated to achieve 1-Hz 
resolution.  Each CEST spectrum was then frequency shifted, using the corresponding WASSR 
spectrum (166), to account for B0 variation. B0 variations were corrected on a pixel-by-pixel 
basis. The three pre- and three post-injection CEST spectra were summed following B0 
corrections to increase signal to noise ratio. A B1 field map was generated using an actual flip-
angle imaging (AFI) pulse sequence (TR = 20 ms, TE = 3.47 ms, echoes = 2, flip-angle = 70°, 
FOV = 25.6 x 25.6 mm2, matrix size= 64 x 64) in a subset of mice (N=3) to verify that the B1 
variation was similar to that found in previous studies using the same experimental setup. The B1 
variation in the CEST slice was less than 5%, so no B1 correction was necessary (85). 
2.2.6 CEST data processing 
All acquired CEST MR data were loaded into MATLAB (Mathworks, Natick, MA, USA) for 
analysis. Using custom MATLAB programs previously described (85,86), B0 corrections were 
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performed on a pixel-by-pixel (86) basis and all CEST spectra were smoothed using the ‘smooth’ 
algorithm from the MATLAB curve fitting toolbox. 
 
2.2.7 CEST and contrast calculations 
Using B0-corrected (166) and smoothed CEST spectra, AACID values were measured on a 
voxel-by-voxel basis. AACID represents the ratio of the CEST effects of the amine protons 
resonating at 2.75 ppm and the amide protons at 3.50 ppm, normalized by magnetization transfer 
(MT) effects measured after saturation at 6.0 ppm.  AACID was calculated using equation (1) 
(60).   
𝐴𝐴𝐶𝐼𝐷 =
𝑀𝑍3.5 𝑝𝑝𝑚×(𝑀𝑍6.0 𝑝𝑝𝑚−𝑀𝑍2.75 𝑝𝑝𝑚)
𝑀𝑍2.75 𝑝𝑝𝑚×(𝑀𝑍6.0 𝑝𝑝𝑚−𝑀𝑍3.5 𝑝𝑝𝑚)
               (1) 
The change in pH following drug administration was obtained using the calibration provided by 
Equation (8) in McVicar et. al. 
∆𝑝𝐻 = −4 × ∆𝐴𝐴𝐶𝐼𝐷                     (2) 
 
2.2.8 Statistical Analysis 
Average AACID values were calculated before and after injection of DCA as well as before and 
after injection of PBS, within contralateral tissue and tumor regions of interest (ROIs) defined in 
each mouse brain using MATLAB (‘roipoly’ function). The ROI was drawn manually around the 
tumor using the hyperintense tissue region observed in the T2-weighted images (Figures 2.1 and 
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2.2) as a guide.  The ROI on the contralateral side was also drawn manually to be similar in size 
to the ROI used for each tumor and was positioned to mirror the location of the tumor in the 
opposite hemisphere. A paired t-test was used to calculate differences in mean AACID values 
measured in the tumor and in contralateral ROIs before and after injection of DCA or PBS 
(control). 
2.3 Results  
AACID CEST maps were successfully acquired in all animals. Anatomical FSE MR images 
acquired 15 ±1 days after U87MG cancer cell implantation were used to identify regions of 
interest in the tumor and on the contralateral side (Figures 2.1c and 2.2c). AACID CEST maps 
showed the expected decrease in AACID value in the tumor region compared to the surrounding 
tissue (Figures 2.1a and 2.2a) indicating a relatively basic intracellular tumor pH. Following 
injection of PBS only, there was little detectable change in the AACID map (Figures 2.1b and 
2.1d). In contrast, an increase in tumor AACID value is clearly visible within the tumor (Figure 
2.2b) indicating intracellular acidification within 60 minutes of DCA injection (Figure 2.2d). 
Pooling all data following PBS injection, no change in AACID value was observed in the tumor 
or within contralateral tissue (Figure 2.3a).  However, one hour after DCA injection there was an 
average increase in AACID value of 0.04±0.01 (N=6, p=0.02) in the tumor region (Figure 2.1d, 
2.3b), but no change in AACID value within contralateral tissue (Figure 2.3b). The measured 
change in AACID value within the tumor corresponds a 0.16 decrease in intracellular pH. 
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Fig 2.1 Mouse brain with GBM tumor 14 days after implantation: a) baseline AACID map 
prior to PBS intravenous injection, b) the AACID map one hour post PBS intravenous 
injection c) coronal fast spin-echo anatomical image shows regions of interest (ROIs) in the 
tumor (dashed white line) and on the contralateral side (solid white line) and d) AACID 
difference maps for the same brain post-pre PBS injection. 
Fig 2.2 Mouse brain with GBM tumor 14 days after implantation: a) baseline AACID map 
prior to DCA intravenous injection, b) the AACID map one hour post DCA intravenous 
injection c) coronal fast spin-echo anatomical image shows regions of interest (ROIs) in the 
tumor (dashed white line) and on the contralateral side (solid white line) and d) AACID 
difference maps for the same brain post-pre DCA (200 mg/kg) intravenous injection. 
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Tables 
Table 2.1: AACID Values Following DCA Injection: 
 
 
 
DCA injection 200 mg/kg 
Mouse 
No. 
AACID Pre 
Contralateral 
STD 
Pre 
AACID Post 
Contralateral 
STD 
Post 
AACID Pre 
Tumor  
STD 
Pre 
AACID Post 
Tumor  
STD 
Post 
1 1.229 0.029 1.242 0.013 1.079 0.018 1.096 0.020 
2 1.327 0.010 1.334 0.013 1.205 0.011 1.246 0.010 
3 1.314 0.011 1.344 0.011 1.198 0.013 1.266 0.011 
4 1.348 0.023 1.320 0.011 1.157 0.008 1.205 0.006 
5 1.266 0.023 1.218 0.016 1.212 0.015 1.195 0.018 
6 1.273 0.017 1.263 0.010 1.127 0.013 1.212 0.016 
Average 1.292 0.019 1.287 0.012 1.163 0.013 1.203 0.013 
Fig 2.3 Average AACID values in tumor and contralateral ROIs: a) pre and post 
intravenous PBS injection as control (N=3). b) pre and post DCA 200 mg/kg intravenous 
injection (N=6). Error bars represent the standard error of the mean. The asterisks indicated 
p<0.05 in repeated measures t-test. 
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Table 2.2:  AACID Values Following PBS Injection: 
 
PBS injection 
Mouse 
 
AACID Pre 
Contralateral 
STD 
Pre 
AACID Post 
Contralateral 
STD 
Post 
AACID Pre 
Tumor  
STD 
Pre 
AACID  
Post Tumor  
STD 
Post 
1 1.303 0.006 1.246 0.006 1.144 0.018 1.140 0.015 
2 1.280 0.006 1.280 0.008 1.239 0.011 1.205 0.007 
3 1.344 0.018 1.365 0.018 1.147 0.015 1.181 0.012 
Average 1.309 0.011 1.297 0.011 1.176 0.014 1.175 0.011 
 
 
2.4 Discussion 
This study demonstrates a tumor selective increase in the AACID CEST MRI signal suggesting 
intracellular acidification in a GBM mouse brain tumor model during the first hour after 
intravenous injection of a single dose of DCA (200 mg/kg).  The AACID CEST MRI signal 
change was estimated to be the result of a ~0.16 pH decrease based on previous calibrations.  In 
contrast, there was no change in the AACID CEST MRI signal on the contralateral side after 
DCA injection, or within tumors or contralateral tissue following PBS injection. DCA is 
approved for human consumption, is generally well tolerated (160), and has been tested as 
treatment in a variety of cancers including glioblastoma (167). 
 DCA is an anticancer agent that alters metabolism and pHi (161,168).  Previous studies 
have suggested that intracellular pH may increase in cancer cells following DCA treatment as a 
direct consequence of the downregulation of glycolysis by DCA (161,168).  Specifically, an 
increase in intracellular pH is possible because DCA is expected to increase glucose oxidation 
and therefore decrease the production of lactic acid within the tumor (161,168).  However, the 
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current in vivo study contradicts these previous in-vitro studies. One potential explanation for 
these unexpected results is that DCA has also been shown to decrease the expression of 
monocarboxylate transporters and V-ATPases in tumor cells but not in normal cells (163). 
Cancer cells also have a higher expression of monocarboxylate transporters and V-ATPases 
compared to normal cells.  Since DCA acts to decrease the expression of these transporters it is 
expected to have a more pronounced effect in cancer cells compared to normal cells.  
The contribution of amide, amine, and aliphatic signals to different tissue types and 
cancers is an area of active research (169). The use of CEST MRI contrast to monitor 
intracellular pH has many potential applications in cancer detection and treatment optimization 
including the differentiation of recurrent glioma from radiation necrosis (14). The AACID CEST 
measurement of tissue pH used in the current study has been shown to be independent of protein 
concentration, tissue T1 relaxation, and temperature (60).  Although the absolute value of 
intracellular pH measurement in tumors with AACID remains to be verified, in the current study, 
AACID was used to measure acute pH change following pharmacologic challenge.  The AACID 
CEST measurement of tissue pH used in the current study incorporates contributions from the 
extracellular and intracellular compartments but is predominantly weighted to the intracellular 
space due to the distribution of amine and amide protons.  The paradigm of using a drug 
designed to manipulate intracellular pH monitored by AACID CEST MRI is akin to 
pharmacologic MRI using the blood oxygen level dependent (BOLD) contrast (170). Such 
methods have several potential advantages over conventional gadolinium based contrast agents.  
First, the contrast produced is based not simply on accumulation of a contrast agent, but rather is 
related directly to the physiology of the tissue, or tumor.  Second, use of different drugs 
approved in humans provides an opportunity to test the effect of blocking different biological 
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mechanisms of pH control.  Different cancers may respond differently to each drug.  Finally, 
gadolinium-based contrast agents have the potential for side effects that are different from those 
produced by drugs like DCA and must be used with caution in patients with kidney disease.  
Gadolinium is also expensive compared to drugs such as DCA.  The physiological information 
obtained from measurement of intracellular pH changes may also provide information regarding 
the response of a tumor to specific a treatment. This idea is supported by Sagiyama et. al. (8) 
who found that amide proton CEST could detect temozolomide treatment effects one week after 
treatment. 
 
In previous studies using the same methodology to evaluate the magnitude of tumor 
acidification we found that lonidamine, a lactate transport inhibitor, decreased intracellular tumor 
pH by 0.25 (dose: 50 mg/kg), and by 0.45 (dose: 100 mg/kg) (85).  In addition, topiramate, a 
carbonic anhydrase inhibitor, decreased intracellular pH by 0.17 (86) at a dose of 120 mg/kg. 
Topiramate is approved for use in humans as an anti-seizure medication, but lonidamine is not 
currently approved in humans.  At the dose used in the current study (200 mg/kg), DCA was not 
as effective as lonidamine but was similar to topiramate with regard to tumor acidification. The 
DCA dose (200 mg/kg) studied is commonly used in the literature for animal studies (46,47). 
Pharmacologic agents that maximize cancer cell acidification would provide the greatest image 
contrast for pharmacological AACID CEST MRI. Modulation of tumor metabolism and acidity 
also represent an interesting and emerging target for anti-cancer treatment, either alone or in 
combination with other existing treatments.  Drugs that interfere with tumor metabolism could 
help enhance chemotherapy and radiation therapy.  In addition, tumor intracellular acidification 
could decrease resistance of the tumor to weakly basic drugs such as Doxorubicin and trigger 
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apoptosis in cancer cells (46-49).  Acidification of the intracellular environment by regulation of 
the intracellular pH is known to induce apoptosis in cancer cells even in a neutral extracellular 
pH (pHe) (48). An acidic pHi may also be responsible for the activation of caspases in cancer 
cells and induce DNA fragmentation (49). An acidic intracellular tumor environment may 
significantly disturb tumor cell proliferation and growth (49). 
 
The current study has several limitations that should be considered. First, the number of 
animals used was small.  However, the effect sizes are large and the ROI based pH 
measurements have low variability.  In addition, the test-retest design eliminates inter-subject 
variation. Therefore the animal numbers used were sufficient to determine whether DCA 
produced a measurable pH effect.   Second, the AACID CEST MRI measurement of pH is based 
on changes in amine and amide proton exchange rate.  The decrease in intracellular pH detected 
in the current study using the AACID CEST method could be verified in a future study using 31P 
magnetic resonance spectroscopy.  Third, we did not optimize the dose of DCA used in the 
current study.  Previous studies have used doses ranging from 25-200 mg/kg (47).  The high dose 
chosen in the current study was attempted to increase the likelihood that we would observe an 
effect based on previous work (46,164).  Future studies could consider higher doses of DCA 
since limited side effects are expected after a single dose. Finally, DCA has multiple mechanisms 
of action that could alter tissue pH. In the current study, we did not examine the effect of chronic 
administration of DCA on tumor pH. Future studies should examine whether repeat exposures 
would lead to decreased or increased tumor pHi. 
 In summary, we found that 200 mg/kg of DCA could induce acute (within 1h) tumor 
AACID CEST MRI signal change likely resulting from intracellular acidification (corresponding 
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to a pH decreases of 0.16) in a mouse model of glioblastoma.  Since DCA is safe for use in 
humans, further evaluation of AACID CEST MRI in glioblastoma patients could incorporate the 
use of this drug to induce a measurable signal change. 
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Abstract: 
Glioblastoma is an aggressive brain cancer that is very difficult to treat. Clinically, it is important 
to be able to distinguish aggressive from non-aggressive brain tumors. Previous studies have 
shown that some drugs can induce a rapid change in intracellular pH that could help to identify 
aggressive cancer. The sodium proton exchanger (NHE1) plays a significant role in maintaining 
pH balance in the tumor microenvironment. Cariporide is a sodium proton exchange inhibitor. 
We hypothesized that cariporide could selectively acidify brain tumors. The purpose of this study 
was to determine whether amine/amide concentration independent detection (AACID) chemical 
exchange saturation transfer (CEST) MRI measurement of tumor pHi could detect acidification 
after cariporide injection. Using a 9.4T MRI scanner, CEST spectra were acquired in six mice 
approximately 14 days after implanting 105 U87 human glioblastoma multiforme cells in the 
brain, before and after administration of cariporide (dose: 6 mg/kg) by intraperitoneal injection. 
Three additional mice were studied as controls and received only vehicle injection 
(DMSO+PBS). Repeated measures t-test was used to examine changes in tumor and contralateral 
tissue regions of interest. Two hours after cariporide injection there was a significant 0.12±0.03 
increase in tumor AACID value corresponding to a 0.48 decrease in pHi, and no change in 
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AACID value in contralateral tissue. A small but significant increase of 0.04±0.017 in tumor 
AACID value was also observed following vehicle injection.  This study demonstrates that acute 
CEST MRI contrast changes indicative of intracellular acidification after administration of 
cariporide could help localize glioblastoma. 
 
3.1 Introduction 
Gliomas are the most common primary brain tumors of the central nervous system 
(CNS). Glioblastoma multiforme (GBM) is one of the most aggressive and deadliest gliomas. 
The treatment for GBM tumors usually includes surgical resection of the primary tumor followed 
by aggressive concurrent radiation and chemotherapy (6-8,171). However, these cancer cells 
often migrate away from the primary tumor and avoid treatment, resulting in recurrence in more 
than 90% of cases (171). Although new treatment strategies continue to be tested, people with 
GBM typically survive only 12-18 months following diagnosis (7,8,171).  Due to their 
aggressive nature and high rate of recurrence, glioblastomas are considered to be one of the 
greatest challenges in the treatment of cancer [1-4].   
 An emerging hallmark feature of solid tumors is the maintenance of an alkaline 
intracellular pH (pHi) and an acidic extracellular pH (pHe) (22,27). In normal cells the pHe is 
higher (~7.4) than the pHi of ~ 7.0-7.1 (24,28-32).  However, the pH gradient in cancer cells is 
reversed with lower pHe (~6.7–7.1) than pHi ~7.1-7.3 (24,28-32). This altered pH homeostasis is 
the consequence of increased aerobic glycolysis even in the presence of oxygen, known as the 
Warburg effect (16). To remove acid metabolites that would accumulate due to the Warburg 
effect, cancer cells increase their expression of regulators that extrude H+ and lactate. However 
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cancer cells overcompensate, producing a relatively alkaline pHi. There are many potential pH 
regulators involved in this process including: Na+/HCO3– co-transporters, Na+/H+ exchangers, 
monocarboxylate transporters, the vacuolar ATPase, carbonic anhydrase, anion exchangers, the 
Cl-/HCO3
- exchangers, and ATP synthase (25,26). The resulting alkaline pHi benefits the cancer 
by supporting increased cell proliferation and evasion of apoptosis (22,33), and can increase the 
resistance of the tumor to chemotherapy and immunotherapy (34). Acidification of the tumor 
intracellular pH has the potential to decreased cell proliferation and induce apoptosis resulting in 
cell death (26,158). 
The purposeful modulation of tumor intracellular pH combined with measurement of the 
pH change has been used to predict tumor response to chemotherapy and radiation therapy 
(8,25,44). One method that is particularly well suited to monitoring tumor pHi is chemical 
exchange saturation transfer (CEST) magnetic resonance imaging (MRI), which provides high-
resolution pH maps in a reasonable scan time (60). Using this approach, we have previously 
shown that lonidamine a monocarboxylate transport inhibitor, topiramate a carbonic anhydrase 
inhibitor, and dichloroacetate, which decreases the expression of monocarboxylate transporters 
and V-ATPases, all selectively cause rapid and measurable in-vivo acidification of glioblastoma. 
To make these measurements, we used a CEST technique called amine and amide concentration-
independent detection (AACID) that uses the ratio of CEST effects of amide (  = 3.5ppm) and 
amine ( = 2.75ppm) protons to generate pHi dependent contrast independent of tissue 
macromolecule concentration and temperature (60). Using AACID-CEST MRI we previously 
found a single dose of lonidamine (LND) decreased tumor pHi by 0.45 (85), a single dose of 
topiramate decreased pH by 0.17 (86), and a single dose of dichloroacetate decreased pH by 0.16 
(88) approximately 1-1.5 hours after injection. Since pH modulation by a single pharmacologic 
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agent will likely be compensated by other mechanisms over time, it is important to identify 
additional drugs that could inhibit other key pHi-regulators and glycolytic enzymes to modulate 
pHi.   
Cariporide is an anticancer agent that alters metabolism and pHi by selectively inhibiting  
 the sodium proton (Na+/H+) exchange isoform 1 (NHE1) (172) with little effect on other ion 
transport systems (173). NHE1 plays a significant role in maintaining the acidic pHe and alkaline 
pHi in malignant tumors, and regulating cell volume (110). It is activated by growth factors and 
cellular proliferation processes (174). In cancer cells, cariporide effectively inhibits NHE1 and 
has been shown to suppress the invasion and migration of cancer cells (175). Cariporide has 
already been tested in vitro in U87 and C6 glioma models.  Cariporide was able to decrease 
intracellular pH of U87 and C6 glioma cells each by 0.3 units within 120 min (111,176). 
Furthermore, in a study of human tongue carcinoma cells (Tca8113) under hypoxic conditions, 
treatment of cells with cariporide for 24h decreased pHi in a dose-dependent manner (175). 
Cariporide has also been shown to decrease proliferation and migration of human umbilical vein 
endothelial cells in vitro (177). In addition, cariporide was shown to have anti-angiogenetic 
effects in vitro and in vivo (177).  Specifically, cariporide decreased intracellular pH and down-
regulated vascular endothelial growth factor (VEGF) secretion in K562 leukemia and inhibited 
K562 tumor growth reducing the density of microvessels in mice. These in vitro studies motivate 
the current work to examine the in vivo effectiveness of cariporide in decreasing glioblastoma 
pHi. An orthotopic U87MG mouse model of glioblastoma was used for the current work because 
this model is known to recapitulate many of the physiological features of the human disease and 
is ideally suited for the application of ultra high field AACID CEST MRI for pH measurement. 
The purpose of this study was to quantify the in vivo acidification of glioblastoma following 
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cariporide treatment by mapping tumor pHi using AACID CEST MRI. We hypothesized that 
blockage of the sodium proton (Na+/H+) exchange isoform 1 (NHE1) by cariporide would 
produce acute intracellular acidification detectable by AACID CEST MRI. The measurement of 
single-dose drug induced acidification could help predict tumor response to treatment or 
potentially provide information on tumor extent and aggressiveness. 
3.2 Experimental 
3.2.1 Subjects 
Twelve female Crl:Nu-Foxn1Nu (NU/NU) mice (Charles River Laboratories, Canada) adult mice 
were included in the current study in three groups. Six NU/NU mice with U87MG brain tumors 
were used to evaluate the effect of cariporide on tumor pHi, three NU/NU mice with U87MG 
brain tumors were injected with phosphate buffered saline (PBS) and dimethyl sulfoxide 
(DMSO) as controls, and three NU/NU mice without tumors were used to study the effect of 
cariporide on normal brain. One additional mouse with tumor was used for hematoxylin and 
eosin (H&E) staining. Mice were group housed in ventilated racks on a 12h/12h light/dark cycle. 
All animal procedures were performed according to a protocol that was consistent with 
guidelines established by the Canadian Council on Animal Care and was approved by the 
University of Western Ontario Animal Use Subcommittee. 
  
3.2.2 Cariporide 
Cariporide is a selective Na+/H+ exchange inhibitor with linear formula C12H17N3O3S. The drug 
was purchased from Cayman Chemical Company (Ann Arbor, Michigan, USA). The drug was 
dissolved in DMSO and diluted with PBS (1:19). The DMSO was purchased from Sigma 
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Aldrich Canada. Cariporide was administered by intraperitoneal (i.p.) injection at a dose of 6 
mg/kg in 1 ml over the course of 2 minutes.  Control mice with brain tumors received an i.p. 
injection of PBS+DMSO only. 
 
3.2.3 Animal model of glioblastoma  
U87MG glioma cells established from a human GBM (ATCC; Rockville, MD, USA) were used 
to induce GBM brain tumors in 22-27g, NU/NU mice (N=6) as described previously in detail 
(86,88,165).  Briefly, Dulbecco’s modified Eagles’s medium supplemented with 10% fetal 
bovine serum (Wisent Inc., St-Jean-Baptiste, QC, Canada) was used to grow the U87MG cells at 
37oC in a humidified incubator with 5% CO2. Cells were passaged twice a week. On the same 
day as the injection into the brain, the U87MG cells were washed and dissociated with versene 
solution (phosphate-buffered saline (PBS) plus 0.5 mM EDTA). Cells were then washed twice 
with PBS, counted and re-suspended to achieve a final concentration of 1 x 105 cells in 2 μl PBS. 
For injection of the cells, mice were anesthetized using 4% inhaled isoflurane and maintained 
using 1.5% isoflurane mixed with 100% oxygen. A stereotactic head frame (Stoelting 
instruments, Wood Dale, IL, USA) was used to guide injections through a hole drilled 1 mm 
anterior and 2 mm lateral from the bregma. Using a Hamilton (Reno, NV, USA) syringe with a 
27-gauge needle attached, U87MG cells (2 μl) were injected at a position 3 mm deep from the 
bregma into the right frontal lobe at a rate of 0.5 l/min.  
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3.2.4 General mouse preparation for in-vivo imaging 
The mice were scanned using a 9.4 T small animal MRI system equipped with a 30 mm 
millipede volume coil (Agilent, Palo Alto, CA, USA) 15 ±1 days after cancer cell injection as 
previously described (86,88).  Briefly, mice were anesthetized using 4% isoflurane in oxygen 
and maintained during scanning with 1.5%–2.5% isoflurane in oxygen. A custom-built MRI-
compatible stage and a bite bar were used to secure the head. Surgical tape was also used to limit 
motion due to respiration. A respiratory sensor pad connected to a pressure transducer that was 
placed on the thoracic region was used to monitor respiration rate. Warm air blown over the 
animal using a model 1025 small-animal monitoring and gating system (SA Instruments Inc., 
Stony Brook, NY, USA) was used to maintain body temperature at 36.9-37.1oC throughout 
imaging, monitored by a rectal probe. After the baseline pre-injection images were acquired, the 
mouse was injected with cariporide inside the MRI by delivering the drug through fine plastic 
tube ended with a needle positioned to achieve intraperitoneal injection. Animals were sacrificed 
immediately after MR imaging. 
 
3.2.5 In-vivo Magnetic Resonance Imaging 
The tumor was initially localized using T2-weighted images. The T2-weighted images were 
acquired using a 2-dimensional fast spin echo pulse sequence (FSE) with parameters: TR/TE = 
3000/10 ms, echo train length (ETL) = 4, effective TE = 40 ms, FOV = 25.6 x 25.6 mm2, matrix 
size = 128 x 128, slice thickness= 1 mm. Two slices from the stack of T2-weighted images were 
selected to provide maximum tumor coverage (2 mm thickness) for CEST imaging. The CEST 
images were acquired using the same methodology as previously used to study the effects of 
lonidamine, topiramate, and dichloroacetate (85,86,88).  Briefly, a fast spin-echo (FSE) pulse 
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sequence was used (TR/TE = 7000/7 ms, ETL = 32, effective TE = 7 ms, FOV = 25.6 x 25.6 
mm2, matrix size = 64 x 64, slice thickness = 2 mm, acquisition time ≈ 18 minutes) preceded by 
a continuous wave radiofrequency (RF) pulse with amplitude 1.5-µT and 4s duration. Saturation 
frequencies were varied from 1.2 to 4.5 ppm and from 5.4 to 6.6 ppm with step size of 0.1 ppm.  
Images were also acquired with saturation frequencies of -1000 and 1000 ppm as references, 
producing a total of 49 images. A complete series of CEST images were acquired three times 
before and three times after drug injection to improve signal-to-noise ratio. The water saturation 
shift referencing (WASSR) technique was used for B0 correction (166) also described previously 
(85,86,88). A linearly spaced 37-point WASSR CEST spectrum (acquisition time ≈ 9 minutes) 
with saturation frequencies ranging from -0.6 – 0.6 ppm was acquired using the same pulse 
sequence except using a short (100 ms) low amplitude (0.2 µT) RF saturation pulse. Each 
WASSR spectrum (166) and CEST spectrum was interpolated to achieve a 1-Hz resolution.  
Each CEST spectrum was then frequency shifted, using the corresponding WASSR spectrum 
(166), to account for B0 variation. B0 variations were corrected on a pixel-by-pixel basis. 
Following B0 corrections the three pre- and three post-injection CEST spectra were summed to 
increase signal to noise ratio. 
 
3.2.6 CEST data processing 
All CEST image processing was performed on a pixel-by-pixel basis using custom MATLAB 
(Mathworks, Natick, MA, USA) code. All CEST spectra were smoothed using the ‘smooth’ 
algorithm from the MATLAB curve fitting toolbox. Each WASSR spectrum and CEST spectrum 
was interpolated to a resolution of 1-Hz.  Each CEST spectrum was then frequency shifted, using 
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the corresponding WASSR spectrum, to account for B0 variation. The three pre- and three post-
injection CEST spectra were summed following B0 corrections to increase signal to noise ratio. 
 
3.2.7 CEST and contrast calculations 
AACID values were calculated on a pixel-by-pixel basis using the associated B0-corrected and 
smoothed CEST spectra. The AACID value represents the ratio of the CEST effects of the amine 
protons that resonate at 2.75 ppm and the amide protons that resonance at 3.50 ppm. 
Macromolecule MT effects were minimized by measuring the CEST effect relative to the 
saturation observed at 6.0 ppm. The AACID value was calculated using Equation (1) (60). 
 
 𝐴𝐴𝐶𝐼𝐷 =
𝑀𝑍3.5 𝑝𝑝𝑚×(𝑀𝑍6.0 𝑝𝑝𝑚−𝑀𝑍2.75 𝑝𝑝𝑚)
𝑀𝑍2.75 𝑝𝑝𝑚×(𝑀𝑍6.0 𝑝𝑝𝑚−𝑀𝑍3.5 𝑝𝑝𝑚)
                                     (1) 
Following drug administration, the change in pH was estimated by Equation (2) obtained using 
the calibration provided by Equation 8 in McVicar et. al. (60). 
∆𝑝𝐻 = −4 × ∆𝐴𝐴𝐶𝐼𝐷         (2) 
 
3.2.8 Statistical Analysis 
Regions of interest (ROIs) were manually defined within tumor tissue and contralateral tissue in 
each mouse brain using MATLAB (‘roipoly’ function).  The ROIs containing tumor tissue were 
drawn manually based on the signal changes observed in the T2-weighted images. The ROIs 
drawn on the contralateral side were chosen to be similar in size and position to the tumor ROI 
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for each mouse.  An average AACID value was calculated before and after injection of 
cariporide or vehicle within each tissue ROI. Differences in mean AACID values measured in 
the tumor and in contralateral ROIs before and after drug or vehicle injection were assessed 
using a paired t-test with p<0.05 considered statistically significant. A similar comparison was 
made in control mice after drug injection using the AACID values from the whole brain. For 
control animals a whole brain ROI was drawn manually using the standard T2-weighted 
anatomical images. 
3.3 Results 
Animals were scanned 15 ±1 days after U87MG cancer cell implantation.  The anatomical FSE 
MR images were used to visualize and draw ROIs in the tumor and on the contralateral side 
(Figures 3.1a and 3.2a). The average weight of the mice at the time of imaging is 22-25g. Prior to 
drug injection AACID CEST maps showed a lower AACID value in the tumor region compared 
to the surrounding tissue as expected (Figures 3.1b and 3.2b) indicating a relatively basic 
intracellular tumor pH.  Following injection of vehicle only (PBS+DMSO), there was a small but 
significant average increase (Figure 3.1c, 3.3a, 3.4a) in the AACID value within the tumor but no 
significant change within contralateral tissue. The post-baseline difference image (Fig 3.3a) 
shows a relatively constant change throughout the brain and tumor region.  Following injection 
of cariporide in PBS+DMSO, a significant increase in tumor AACID value of 0.21±0.02 (N=6, 
p<0.05) is visible within the tumor (Figure 3.2c) indicating intracellular acidification within 2 
hours of cariporide injection. There was no change in AACID value within contralateral tissue 
(Figure 3.4b).  The post-baseline difference image (Figure 3.3b) shows a larger effect (Figure 
3.4b) compared to vehicle alone.  The measured change in AACID value within the tumor after 
cariporide injection corresponds to a 0.48 decrease in intracellular pH, estimated using Equation 
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2. In further control experiments, there was no change in AACID value in normal brain 
following injection of cariporide in PBS+DMSO (Figures 3.5 and 3.6).  
Figure 3.7 shows H&E staining in a mouse with a typical brain tumor that demonstrates the size, 
localization, and homogeneity of the tumor tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Mouse brain with GBM tumor 15 ±1 days after implantation: a) coronal 
fast spin-echo anatomical image showing regions of interest (ROIs) in the tumor 
(dashed white line) and on the contralateral side (solid white line), b) the 
corresponding baseline AACID map prior to PBS+DMSO intraperitoneal injection, 
and c) the corresponding AACID map two hours post PBS+DMSO intraperitoneal 
injection. 
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Figure 3.2 Mouse brain with GBM tumor 15 ±1 days after implantation: a) coronal 
fast spin-echo anatomical image showing regions of interest (ROIs) in the tumor 
(dashed white line) and on the contralateral side (solid white line), b) the 
corresponding baseline AACID map prior to cariporide injection, and c) the 
corresponding AACID map two hours post cariporide (6 mg/kg) intraperitoneal 
injection. 
Figure 3.3 Mouse brain AACID difference maps for the same brains: a) post 
PBS+DMSO injection - baseline, b) post cariporide (6 mg/kg) injection - 
baseline. intraperitoneal injection. 
Figure 3.4 Average AACID value in tumor and contralateral ROIs: a) pre and post 
intraperitoneal PBS+DMSO injection as control (N=3). b) pre and post cariporide (6 
mg/kg) intraperitoneal injection (N=6). Error bars represent the standard error of the 
mean. The asterisks indicated p<0.05 in repeated measures t-test. 
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Figure 3.5 Normal mouse brain: a) T2-weighted image b) AACID map prior to 
cariporide injection c) AACID map post cariporide intraperitoneal injection. 
Figure 3.6 Average AACID value in normal brain ROIs on the left side, right side 
and whole brain: a) pre and post cariporide (6 mg/kg) intraperitoneal injection N=3. 
 
Figure 3.7 H&E stained brain section from a representative mouse with U87 glioblastoma 
multiforme (GBM) brain tumor. (a) Whole brain section. (b) Magnified region 
corresponding to the black box in (a) showing the boundary of the tumor within the brain. 
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3.4 Discussion  
This study is the first to demonstrate changes in AACID CEST MRI indicative of 
intracellular acidification in orthotopic U87MG brain tumors within the first two hours after i.p. 
injection of a single dose of cariporide (6 mg/kg). The side contralateral to the tumor showed no 
change in the AACID value after cariporide injection. It is also noteworthy that the vehicle 
(PBS+DMSO) alone produced a small but measurable increase in AACID value within tumors. 
Cariporide is an anticancer agent (172) that alters pHi by inhibiting the Na
+/H+ exchange 
isoform-1 (NHE-1). Cariporide is not expected to cross an intact blood-brain barrier (178,179), 
however under ischemic conditions (178), and in cancer (180), it has been shown to enter the 
affected tissue. The results of the current study are consistent with several previous reports that 
have shown that the inhibition of Na+/H+ exchange using cariporide decreased intracellular pH in 
human umbilical cord derived mesenchymal stem cells (hUC-MSCs) (181) as well as human 
tongue carcinoma (175) and K562 leukemia cells (182). 
We have previously used the same methodology to evaluate the magnitude of tumor 
acidification following administration of the drugs lonidamine, topiramate, and DCA.  
Lonidamine, a monocarboxylate transport inhibitor, decreased intracellular pH by 0.25 at a dose 
of 50 mg/kg and decreased intracellular pH by 0.45 at a dose of 100 mg/kg (85). Topiramate, a 
carbonic anhydrase inhibitor, decreased intracellular pH by 0.17 (86) at a dose of 120 mg/kg. 
More recently we also showed that giving 200 mg/kg of dichloroacetate which decreases the 
expression of monocarboxylate transporters and V-ATPases, decreased intracellular pH by 0.16 
(88). At the dose studied in the current work, cariporide had a similar effect on intracellular pH 
as 100 mg/kg lonidamine. However, cariporide has been tested in humans for cardiac 
applications, but at the doses studied showed some toxicity and is not currently approved for 
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humans.  Further studies are needed to determine the utility of combing a pharmacologic 
challenge using cariporide in combination with CEST MRI for cancer detection.  It should be 
noted that the modification of tumor intracellular pH is emerging as a novel target for anti-cancer 
treatment.  The use of drugs like cariporide to acidify tumors could enhance the effectiveness of 
existing chemotherapies, and could also be used directly to reduce cancer cell proliferation and 
tumor growth (183).    
 There are several limitations to the current work that should be considered when 
interpreting the results. First, cariporide at the dose studied (6 mg/kg) cannot be dissolved in 
distilled water or PBS. Therefore, it was dissolved in DMSO. DMSO alone caused a small 
increase in AACID value suggesting a decrease in intracellular pH. However, this could be an 
advantage for studies aimed at lowering intracellular pH, as long as the concentration of DMSO 
is sufficiently small to limit any toxic effects. Second, in the current study, only one dose of 
cariporide was examined. Future studies should determine whether higher doses of cariporide 
could increase tumor acidification, and whether the effect is repeatable after multiple exposures. 
Third, the number of animals included in the current study was small. However due to the large 
change induced by the drug, more animals were not needed in this proof of principle study. It 
should also be noted that the use of AACID CEST to measure absolute intracellular pH requires 
further calibration. In the current study, an estimate of the change in pH induced by cariporide 
was made using a previously published calibration performed in the brain under normoxic and 
ischemic conditions (60).  
In conclusion, we found an increase in AACID CEST MRI signal within 2 hours 
following a single dose of cariporide indicating tumor acidification.  The results of the current 
study demonstrate that acute CEST MRI contrast changes after administration of cariporide 
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could help localize brain cancer by rapidly and selectively inducing a shift in intracellular pH. 
Since humans can tolerate cariporide, future studies in people with glioblastoma may be 
warranted to determine whether pharmacologic modulation of tumor pH would aid in cancer 
localization.  
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                                                  Chapter 4 
4   Brain Tumor Acidification using Drugs Simultaneously  
      Targeting Multiple pH Regulatory Mechanisms 
                     Mohammed Albatany, Valeriy Ostapchenko, Susan Meakin, and Robert Bartha 
 
Abstract: 
Non-invasively distinguishing aggressive from non-aggressive brain tumors is an important 
clinical challenge. Intracellular pH (pHi) regulation is essential for normal cell function and is 
normally maintained within a narrow range. Cancer cells are characterized by a reversed 
intracellular to extracellular pH gradient, compared to healthy cells that is maintained by several 
distinct mechanisms.  Previous studies have demonstrated acute pH modulation in glioblastoma 
detectable by chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) 
after blocking individual pH regulatory mechanisms.  The purpose of the current study was to 
simultaneously block five pH regulatory mechanisms while also providing glucose as an energy 
substrate.  We hypothesized that this approach would increase the acute pH modulation effect 
allowing the identification of aggressive cancer.  Using a 9.4T MRI scanner, CEST spectra were 
acquired sensitive to pHi using amine / amide concentration independent detection (AACID). 
Twelve mice were scanned approximately 11±1 days after implanting 105 U87 human 
glioblastoma multiforme cells in the brain, before and after intraperitoneal injection of a 
combination of five drugs (quercetin, cariporide, dichloroacetate, acetazolamide, and 
pantoprazole) with and without glucose.  Two hours after combination drug injection there was a 
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significant 0.1±0.03 increase in tumor AACID corresponding to a 0.4 decrease in pHi.  After 
injecting the drug combination with glucose the AACID value decreased by 0.18±0.03 
corresponding to a 0.72 decrease in pHi. AACID values were unchanged in contralateral tissue. 
The combined drug treatment with glucose produced a large acute CEST MRI contrast indicating 
tumor acidification, which could be used to help localize brain cancer and monitor tumor 
response to chemotherapy. 
4.1 Introduction 
Glioblastoma multiforme (GBM) is a highly aggressive cancer and the most common 
primary brain tumor of the central nervous system (CNS). The current standard of treatment 
combines surgical resection of the primary tumor followed by concurrent radiation and 
chemotherapy (6-8,171,184). However, due to the high migratory nature of GBM cancer cells, 
many escape treatment leading to recurrence in 90% of GBM patients (171). As a result, GBM 
patients often survive only 12-18 months following diagnosis (7,8,171).  In the United States, 
glioblastomas represent the second leading cause of death among neurological diseases and one 
of the greatest challenges in the cure of cancer worldwide (6-8,171).   
 Cancer cells are characterized by a distinctive intracellular/extracellular pH gradient, that 
is reversed compared to normal cells.  Specifically, in cancer cells, the extracellular space is 
acidic and the intracellular compartment is neutral or slightly basic (24,28-32,185).  This reversal 
of the pH gradient in tumors occurs because (16,186) aerobic glycolysis even in the presence of 
oxygen, known as the Warburg effect (16), (186) produces a large quantity of acidic metabolites 
that are exported to the extracellular space. The acidification of the extracellular tumor 
microenvironment contributes to cancer cell evasion of apoptosis (22,33), drug resistance (34), 
proliferation (33), and increased metastatic potential (16,22,24,36-40).  Aggressive tumors often 
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increase in size too quickly to develop adequate vasculature. Therefore cancer cells that favor 
glycolysis tend to have an advantage (16,22,41). High glucose uptake (22,35), which is the basis 
of cancer detection using the glucose analog 18F-labeled fluorodeoxyglucose (18F FDG) positron 
emission tomography (PET) (16), and up-regulation of pro-glycolytic enzymes such as 
hexokinase (16) can lead to further extracellular acidification. 
Conversely, purposefully decreasing tumor intracellular pH can have several potential 
beneficial applications for cancer patients.  For example, the manipulation of tumor intracellular 
pH may predict tumor response to chemotherapy and radiation therapy (8,25,44).  Additionally, 
decreasing intracellular pH in cancer cells may increase the efficacy of some anti-tumor 
treatments (48,49), and may directly induce cancer cell apoptosis (49). Tumor acidification can 
be achieved by blocking the regulators that extrude H+ and lactate, which maintain a relatively 
alkaline tumor pHi.  These regulators include carbonic anhydrase inhibitors, anion exchangers, 
the Cl-/HCO3
- exchangers, Na+/HCO3
– co-transporters, Na+/H+ exchangers, monocarboxylate 
transporters (MCT), and the vacuolar ATPase and ATP synthase (25,26).  We have previously 
shown that blocking specific regulators of pH can acidify the intracellular tumor environment 
within two hours of dosing in a U87 GBM mouse model.  Specifically, we found the MCT 
inhibitor lonidamine decreased pHi by 0.25 at a dose of 50 mg/kg and decreased pHi by 0.45 at a 
dose of 100 mg/kg (85), the carbonic anhydrase inhibitor topiramate 120 mg/kg decreased pHi by 
0.17 (86), the MCT and V-ATPases inhibitor dichloroacetate (200 mg/kg) decreased pHi by 0.16 
(88), the Na+/H+ exchange inhibitor cariporide (6 mg/kg) decreased pHi by 0.48 (187), and the 
MCT inhibitor quercetin (200 mg/kg) decreased pHi by 0.27 (89).  However, it is currently 
unknown whether combining two or more drugs to simultaneously block multiple pH regulatory 
mechanisms can produce greater tumor acidification. 
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 The purpose of the current study was to determine whether acute glioblastoma 
intracellular acidification could be enhanced in-vivo in the U87 GBM mouse model using a 
combined therapy that simultaneously blocked several major pH regulators, and to determine 
whether cancer cell apoptosis increased following short term acidification treatment. We 
hypothesize that combining five drugs targeting different pH regulatory pathways would induce 
greater acidification within tumors than that previously found with only a single drug.  We 
further hypothesized that pre-treatment with glucose to provide additional substrate for aerobic 
glycolysis in combination with the five drug acidification treatment would further increase 
intracellular acidification.  Finally, we hypothesized that short term acidification treatment would 
increase tumor apoptosis.  In all studies, intracellular pH was monitored in-vivo using amine / 
amide concentration independent detection (AACID) chemical exchange saturation transfer 
(CEST) magnetic resonance imaging (MRI). 
4.2 EXPERIMENTAL 
4.2.1 Subjects 
 Nineteen different female Crl:-Nu-Foxn1Nu (NU/NU) (Charles River Laboratories, 
Canada) adult mice were included in the current study. Mice were group housed in ventilated 
racks, on a 12h/12h light/dark cycle. All animal procedures were performed according to a 
protocol that was consistent with the guidelines established by the Canadian Council on Animal 
Care and was approved by the University of Western Ontario Animal Use Subcommittee.   
 For the assessment of the acute intracellular tumor acidification produced by the drug 
combination, six NU/NU mice with U87MG brain tumors were used (Group A1).  An additional 
six NU/NU mice with U87MG brain tumors were used to evaluate the acute intracellular tumor 
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acidification produced by the drug combination preceded by glucose administration (Group A2).  
To assess apoptosis following brief continuous treatment (8 days), three groups of mice were 
studied.  The first group consisted of three mice from Group A1 that were treated with the five-
drug combination (Group T1).  The second group was a control group of three mice with brain 
tumors that received only vehicle (Group T2).  The third group was also a control group of four 
mice without tumors that were treated with the five-drug combination to assess the impact on 
normal brain (Group T3). 
  
4.2.2 Selection of Drugs to Block pH Regulation 
Intracellular acidification can be achieved by inhibiting different regulators of intracellular pH 
including vacuolar H+-ATPases (188,189), Na+/H+ exchangers (190,191), monocarboxylate 
transporters (16,22,192), and carbonic anhydrases (193,194). In each case, drugs already used for 
human use have been shown to inhibit these mechanisms.  We designed a combination therapy to 
simultaneously target these five pH regulatory mechanisms using drugs already approved for 
human use including quercetin, pantoprazole (PPZ), acetazolamide, dichloroacetate (DCA), and 
cariporide.   Quercetin (Sigma –Aldrich, Canada) is an inhibitor of monocarboxylate transporters 
(MCTs) (94,114-117) with linear formula C15H10O7.  It specifically inhibits MCT1 and MCT2 
(114).  The quercetin dose used was 100 mg/kg every 8 hours (195).  Pantoprazole (United States 
Pharmacopeia, Maryland, USA) is a proton pump inhibitor (PPI) with linear formula 
C16H14F2N3NaO4S·1.5H2O that targets the vacuolar H
+-ATPase and has been shown to decrease 
intracellular pH and increase apoptotic cell death in cancer cells (142,143). The pantoprazole dose 
used was 2 mg/kg every 8 hours.  Acetazolamide (Sigma –Aldrich, Canada) with linear formula 
C4H6N4O3S2 inhibits carbonic anhydrase activity and decreases expression of the  aquaporin-1 
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(AQP1) water channel (128-136).  It may also inhibit angiogenesis and endothelial cell 
proliferation in various cancers (137-140). The acetazolamide dose used was 50 mg/kg every 8 
hours.  Dichloroacetate (Sigma –Aldrich, Canada) with linear formula Cl2CHCO2Na inhibits 
pyruvate dehydrogenase kinases (PDKs) and redirects pyruvate back into the mitochondria 
(160,162), which reverses the Warburg effect by activating pyruvate dehydrogenase (PDH).  
However, DCA also decreases the expression of monocarboxylate transporters MCTs and V-
ATPase (163) in tumor cells, leading to reduced pHi in tumors. DCA has been shown to induce 
cell death in several different types of cancer (47,154,155,160,161).  The DCA dose used was 100 
mg/kg every 8 hours.  Finally, cariporide (Cayman Chemical Company, Michigan, USA) with 
linear formula C12H17N3O3S selectively inhibits the Na
+/H+ exchange isoform 1 (NHE1) (172) 
with little effect on other ion transport systems (173) and has been shown to suppress the invasion 
and migration of cancer cells (175). The cariporide dose used was 2 mg/kg every 8 hours. 
 
4.2.3 Drug Delivery 
 
All drugs were obtained in powder form and dissolved in dimethyl sulfoxide (DMSO).  To assess the 
acute effects on pH of the drug combination using CEST MRI (Groups A1 and A2), the drugs were 
injected together in DMSO only without dilution.  Specifically, the single injection contained drug doses 
equal to that used for eight hours of treatment as described above.  To assess whether glucose increased 
tumor intracellular acidification using CEST MRI, glucose (Sigma –Aldrich, Canada) with linear formula 
C6H12O6 was dissolved in PBS and administered by i.p. injection (Group A2) at a dose of 5 g/kg in 0.2 
ml.  Glucose was provided 20 mins before injection of the drug combination.  For mice receiving 
treatment (Groups T1 and T3), the drugs were diluted with phosphate buffered saline (PBS) at a ratio of 
1:19 and administered by intraperitoneal (i.p.)  injection in a total volume of 1 ml every 8 hours for eight 
days. Control mice with brain tumors (Group T2) received DMSO+PBS at a ratio of 1:19 in a total 
volume of 1 ml every eight hours for eight days.   
63 
 
 
 
4.2.4 Animal Model of Glioblastoma  
The GBM animal model has been published previously but is provided for completeness 
(85,88,89,187)  GBM brain tumors were induced in 22-27g, NU/NU mice (N=15) using U87MG 
glioma cells established from a human GBM (ATCC; Rockville, MD, USA) as described 
previously (165).   Briefly, U87MG cells were grown in Dulbecco’s modified Eagles' medium 
supplemented with 10% fetal bovine serum (Wisent Inc., St-Jean-Baptiste, QC, Canada) at 37 oC 
in a humidified incubator with 5% CO2 and passaged twice a week. On the day of injection, 
U87MG cells were washed and dissociated with versene solution (phosphate-buffered saline 
(PBS) plus 0.5 mM EDTA), then washed twice with PBS, counted and re-suspended to a final 
concentration of 1 x 105 cells in 2 mL PBS. Before injection, mice were anesthetized by 
inhalation of 4% isoflurane and maintained using 1.5% isoflurane. The mouse was placed in a 
stereotactic head frame (Stoelting instruments, Wood Dale, IL, USA). The scalp was swabbed 
with betadine, and an incision was made in the scalp to expose the bregma. A 1 mm diameter 
hole was drilled at coordinates measured from the bregma (1 mm anterior and 2 mm lateral). 
U87MG cells (2 µl) were injected at a rate of 0.5 L/min, at a position 3 mm deep from the 
bregma into the right frontal lobe using a Hamilton (Reno, NV, USA) syringe with a 27-gauge 
needle attached.  
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4.2.5 Mouse Preparation for In-vivo Imaging 
Approximately 11±1 days after cancer cell injection, the mice in Groups A1 and A2 were 
scanned on a 9.4 T small animal MRI system equipped with a 30 mm millipede volume coil 
(Agilent, Palo Alto, CA, USA). Anesthesia was induced using 4% isoflurane in oxygen and 
maintained with 1.5%–2.5% isoflurane in oxygen. Each mouse was secured on a custom-built 
MRI-compatible stage, and the head was secured using a bite bar (86) and surgical tape to limit 
motion due to respiration. Animal temperature was monitored with a rectal temperature probe, 
and respiration was monitored with a respiratory sensor pad connected to a pressure transducer 
that was placed on the thoracic region. Body temperature was maintained at 36.9-37.1 oC 
throughout imaging by blowing warm air over the animal using a model 1025 small-animal 
monitoring and gating system (SA Instruments Inc., Stony Brook, NY, USA). Following 
baseline imaging, the mouse was injected with the drug combination inside the MRI through fine 
plastic tube ended with a needle to deliver into the peritoneum. Following imaging, three animals 
from Group A1 were treated with the five drug combination for eight days (Group T1), while all 
others animals were sacrificed immediately after MR imaging. 
 
4.2.6 In-vivo Magnetic Resonance Imaging and pH-weighted imaging 
The imaging protocol used in this study has been published previously (85,88,187).  Briefly, T2-
weighted images were used for tumor detection acquired using a 2-dimensional fast spin echo 
pulse sequence (FSE) with parameters: TR/TE = 3000/10 ms, ETL = 4, effective TE = 40 ms, 
FOV = 25.6 x 25.6 mm2, matrix size = 128 x 128, slice thickness= 1 mm. Two slices from the 
series of T2-weighted images with maximum tumor coverage were selected for CEST imaging. 
CEST images were acquired using a fast spin-echo (FSE) pulse sequence (TR/TE = 7000/7 ms, 
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ETL = 32, effective TE = 7 ms, FOV = 25.6 x 25.6 mm2, matrix size = 64 x 64, slice thickness = 
2 mm) preceded by a continuous wave radiofrequency (RF) pulse with amplitude 1.5-µT and 4s 
duration. The CEST images were acquired at different saturation frequencies (from 1.2 to 4.5 
(∆=0.1) ppm, from 5.4 to 6.6 (∆=0.1) ppm, and -1000 and 1000 ppm images were acquired as a 
reference, total 49 images). A complete series of CEST images were acquired three times before 
and three times after drug injection to improve the signal-to-noise ratio. For B0 correction, the 
water saturation shift referencing (WASSR) technique was used (166). A linearly spaced 37-
point WASSR CEST spectrum with saturation frequencies ranging from -0.6 – 0.6 ppm was 
acquired using the same pulse sequence except preceded by a short RF saturation pulse (100 ms) 
with low amplitude (0.2µT).  
4.2.7 CEST Data Processing 
All acquired CEST MR data were processed on a pixel-by-pixel basis using custom MATLAB 
(Mathworks, Natick, MA, USA) code for analysis as previously described (85,88,89,187). Each 
WASSR spectrum and CEST spectrum was interpolated to achieve 1-Hz resolution.  All CEST 
spectra were smoothed using the ‘smooth’ algorithm from the MATLAB curve fitting toolbox.  
Each CEST spectrum was then frequency shifted, using the corresponding WASSR spectrum, to 
account for B0 variation. B0 variations were corrected on a pixel-by-pixel basis. The three pre- 
and three post-injection CEST spectra were summed following B0 corrections to increase signal 
to noise ratio. As previously shown (85), the B1 variation in the CEST slice was less than 5%, so 
no B1 correction was applied (85).   
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4.2.8 Mapping Tissue Intracellular pH 
Tissue pHi was monitored using amine and amide concentration-independent detection 
(AACID), which uses the ratio of CEST effects from amide ( = 3.5ppm) and amine ( = 
2.75ppm) protons to generate pHi dependent contrast independent of tissue macromolecule 
concentration and temperature (60). The CEST contrast originates from exchangeable amine and 
amide protons that are found in tissue proteins and peptides (14,58,77,159).  However the 
AACID CEST measurement of tissue pH is highly weighted to the intracellular compartment 
(14) because almost 90% of total protein content exists in the intracellular space (77).  AACID 
values were measured on a pixel-by-pixel basis using the associated B0-corrected and smoothed 
CEST spectra. The AACID value represents the ratio of the CEST effects of amine protons 
resonating at 2.75 ppm and amide protons at 3.50 ppm, normalized by MT effects measured after 
saturation at 6.0 ppm and is calculated using equation (1) (60). 
 
𝐴𝐴𝐶𝐼𝐷 =
𝑀𝑍3.5 𝑝𝑝𝑚×(𝑀𝑍6.0 𝑝𝑝𝑚−𝑀𝑍2.75 𝑝𝑝𝑚)
𝑀𝑍2.75 𝑝𝑝𝑚×(𝑀𝑍6.0 𝑝𝑝𝑚−𝑀𝑍3.5 𝑝𝑝𝑚)
                                                         (1) 
Following drug administration, the change in pH was estimated by Equation (2) obtained using 
the calibration provided by Equation (8) in McVicar et al. (60). 
∆𝑝𝐻 = −4 × ∆𝐴𝐴𝐶𝐼𝐷         (2) 
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4.2.9 Immunohistochemistry on mouse brains 
On day 18-19 after injection of cancer cells, mice were euthanized and perfused with 4% 
paraformaldehyde in PBS as described previously (196). After 24-hour incubation in 4% 
paraformaldehyde at 4 C, brains were cut using a vibratome into 80-µm coronal sections. 
Randomly chosen sections containing tumor were then immunostained as described previously 
(197), using an anti-cleaved caspase-3 (CC3) antibody (Cell Signaling, cat#9664, 1:500) and 
Alexa Fluor 488 secondary anti-rabbit antibody (Thermo Fisher, cat#A-11008), followed by 
nuclear staining with Hoechst 33342. Stained brain sections were mounted on glass slides using 
Immu-mount (Thermo Scientific, cat#9990402) and imaged using a FV1000 confocal 
microscope (Olympus) equipped with a 10x/0.4 or a 20x/0.75 objective. Images were stitched 
using FluoView software (Olympus) and analyzed using ImageJ Measure and Cell Counter 
plugins (NIH, Bethesda, MD). At least three sections per animal and at least three animals per 
condition were analyzed. Apoptosis was quantified using the number of CC3-positive cells per 
mm3.   
 
4.2.10 Statistical Analysis 
Regions of interest (ROIs) containing tumor tissue and contralateral tissue were drawn manually 
in each mouse brain using the MATLAB (‘roipoly’ function) using the contrast observed in the 
T2-weighted images as a guide.  Average AACID values were calculated before and after 
injection of the drug combination within each ROI. A paired t-test was used to calculate 
differences in mean AACID values measured in the tumor and contralateral ROIs before and 
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after injection of the drug combination and the drug combination plus glucose.   The number of 
CC3 positive cells per mm3 were compared between treatment groups using a Student’s t-test in 
Prism (GraphPad).   In all comparisons, p<0.05 was considered statistically significant. 
4.3 Results 
AACID CEST maps were acquired in all animals 11 ±1 days after U87MG cancer cell 
implantation. Anatomical FSE MR images were successfully used to identify regions of interest 
in the tumor and on the contralateral side (Figures 4.1c and 4.2c). AACID CEST maps showed 
the expected lower AACID value in the tumor region compared to the surrounding brain tissue 
(Figures 4.1a and 4.2a) indicating a relatively basic intracellular tumor pH. Also, as expected, a 
large increase in tumor AACID value was observed within the tumor following the injection of 
the drug combination (Figure 4.1b) indicating rapid intracellular acidification within 2 hours of 
injection. As expected, the difference between the post and pre images in a single animal showed 
a greater effect in the tumor ROI compared to the contralateral ROI (Figure 4.1d).  Specifically, 
two hours after injection of the drug combination, there was an average increase in the AACID 
value of 0.10±0.03 (N=6, p<0.05) in the tumor region (Figure 4.3a), but no change in AACID 
value within the contralateral tissue (Figure 4.3a). When providing glucose prior to the combined 
drug injection an even larger increase in AACID value was visible (Figure 4.2b) suggesting even 
greater acidification was achieved. When pre-treating with glucose, there was a significant 
increase in the AACID value of 0.18±0.03 (N=6, p<0.0001) two hours after the combination 
drug injection in the tumor region (Figure 4.3b).  However, there was also a small change in the 
AACID value within the contralateral tissue (Figure 4.3b). The difference between the post and 
pre images in a single animal (Figure 4.2d) showed a greater effect in the tumor ROI compared 
to the contralateral ROI as expected. The measured changes in the average AACID value within 
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the tumor after the combination drug treatment corresponded to a 0.4 pH drop, while 
pretreatment with glucose produced a 0.72 pH drop, estimated using Equation 2.  
All animals in Groups T1 and T3 completed eight days of drug treatment.  Representative 
immunostained brain sections showing the results of cleaved (active) caspase 3 (CC3) 
immunostaining as a marker of apoptotic cell death are provided in Figure 4.4.  Control mice 
without tumors showed almost no evidence of CC3 staining (Figure 4.4A).  However, within 
tumors, CC3 staining was increased in the control group (Figure 4.4B, 4.4D) and after treatment 
(Figure 4.4C, 4.4D) in the treatment group.  In the mice treated with the five drug combination 
there was a significant increase in CC3 levels (p=0.0023) (Figures 4.4C, 4.4D). 
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Figure 4.1 Mouse brain with GBM tumor 11 ±1 days after implantation: a) baseline 
AACID map prior to drug injection, b) the AACID map two hours post drug injection, c) 
coronal fast spin-echo anatomical image showing the ROIs in the tumor (dashed white 
line) and on the contralateral side (solid white line), and d) AACID difference maps for 
the same brain post–pre drug injection. 
Figure 4.2 Mouse brain with GBM tumor 11 ±1 days after implantation: a) baseline 
AACID map prior to drug and glucose injections, b) the AACID map two hours post drug 
and glucose injections, c) coronal fast spin-echo anatomical image showing the ROIs in the 
tumor (dashed white line) and on the contralateral side (solid white line), and d) AACID 
difference maps for the same brain post–pre drug and glucose injections.  
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Figure 4.3 Average AACID value in tumor and contralateral ROIs: a) pre and post 
intraperitoneal five drug combination injection (N=6). b) pre and post five drug 
combination + glucose intraperitoneal injection (N=6). Error bars represent the 
standard error of the mean. The asterisks indicated p<0.05 in repeated measures t-
test. 
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Figure 4.4 Cleaved Caspase 3 (CC3) Increases in Tumor after Treatment. (A-C) 
Representative images of coronal brain sections of (A) non-tumor control mice, (B) 
mice with U87 tumors, non-treated receiving vehicle only, and (C) mice with tumors, 
treated for eight days with the five drug combination. Blue corresponds to nuclear 
stain (Hoechst), red corresponds to CC3 (apoptotic marker). Scale bar: 0.4 mm. (D) 
Quantification of apoptotic cells in (A-C). ** indicate p<0.01. 
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4.4 Discussion  
This study demonstrates intracellular acidification in brain tumors two hours after 
injection of a single dose of five drugs designed to block different pH regulatory mechanisms.  
Tumor acidification was further enhanced by pretreatment with glucose.  The magnitude of these 
changes is larger than that reported previously for single drug treatment. In contrast, there was no 
change in brain tissue pH detected on the side contralateral to the tumor after combined drug 
injection, but there was a small decrease in pH on the contralateral side when glucose was given 
prior to the combined drug injection.  Eight days of treatment with the five drug combination 
significantly increased the number of cells positive for cleaved caspase 3 within the tumor. 
 The drug combination used in the current study was designed to block multiple pH 
regulatory mechanisms to enhance the acidification produced by any single compound.  
Quercetin is a natural compound, and a plant product that has been used as a chemotherapeutic 
agent to treat many cancer types(116,117,198). Quercetin is an MCT inhibitor (94,114-117) that 
specifically inhibits MCT1 and MCT2 (114). Pantoprazole (PPZ) has also been shown to be an 
anti-cancer agent (141) due to its ability to induce cancer cell death by inhibiting the V-ATPase 
causing reversal of H+ homeostasis. Acetazolamide induces intracellular acidification by 
inhibiting carbonic anhydrase activity and decreasing aquaporin-1 (AQP1) water channel protein 
expression (128-136). Dichloroacetate (DCA) is a small molecule and has low toxicity compared 
to other anti-cancer agents (155). DCA has been shown to induce cell death in several different 
types of cancer (160,161). DCA inhibits pyruvate dehydrogenase kinases (PDKs) and redirects 
pyruvate back into the mitochondria (160,162), which reverses the Warburg effect by activating 
pyruvate dehydrogenase (PDH).  However, DCA also decreases the expression of 
monocarboxylate transporters and V-ATPase (163) in cancer cells reducing pHi in tumors. 
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Cariporide selectively inhibits the sodium proton (Na+/H+) exchange isoform 1 (NHE1) (172) 
with little effect on other ion transport systems (173). In malignant tumors NHE1 plays a 
significant role in maintaining acidic pHe, alkaline pHi, and regulating cell volume (110). It is 
activated by growth factors and cellular proliferation processes (174). Cariporide effectively 
inhibits NHE1 and has been shown to suppress the invasion and migration of cancer cells (175). 
Cariporide also decreased intracellular pH and down-regulates vascular endothelial growth factor 
(VEGF) secretion in K562 leukemia cells (182).  Therefore, using these specific drugs blocks 
several known pH regulatory mechanisms: Na+/H+ exchange, monocarboxylate transporters 
(MCTs), carbonic anhydrase and aquaporin-1(AQP1), pyruvate dehydrogenase kinases (PDKs) 
and V-ATPase. 
In previous studies using the same methodology to evaluate the magnitude of tumor 
acidification, we found lonidamine decreased pHi by 0.25 at a dose of 50 mg/kg and decreased 
pHi by 0.45 at a dose of 100 mg/kg (85) while topiramate decreased pHi by 0.17 (86). More 
recently we also showed that 200 mg/kg of dichloroacetate decreased pHi by 0.16 (88), and that 6 
mg/kg of cariporide decreased pHi by 0.48 (187). At the dose studied, the combination of drugs 
used in the current study decreased pHi by 0.4 alone and by 0.72 in combination with glucose.  
Although the five drug combination produced a pHi change similar to that shown previously with 
100 mg/kg of lonidamine and 6 mg/kg of cariporide, the combination used in the current study 
used mostly drugs considered safe in humans and used a much lower dose of cariporide (one 
third of that used previously) and DCA (half of that used previously).  The dose was lowered in 
the current study to reduce potential side effects and interactions. 
In an effort to further enhance intracellular acidification, glucose was injected 20 minutes 
prior to drug injection.  Cancer cells readily take up and metabolize glucose more so than normal 
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cells, which forms the basis of cancer detection using fluorodeoxyglucose (18F-FDG) positron 
emission tomography (PET).  The end products of glucose metabolism are protons and lactate, 
which are normally removed from the cell by the pH regulatory mechanism targeted in this 
study.  Blocking these mechanisms 20 minutes after glucose injection produced a much larger 
acute intracellular acidification effect.  The application of several drugs together, in combination 
with glucose achieved greater tumor intracellular acidification than any previous single drug 
studied. 
To study the long-term effect of intracellular acidification on cancer cell viability in-vivo, 
the five-drug combination was given to mice three times per day for eight days.  Within the 
tumor, there was a significant increase in the number of cells staining positive for cleaved 
caspase 3, suggesting an increase in the number of cells undergoing apoptosis.  There were very 
few cells undergoing apoptosis in normal brain, after being given the same drug treatment. These 
in-vivo results are consistent with previous studies of cancer cell lines, which have shown that 
cancer cell acidification can induce apoptosis in a variety of cancer models(149,199-203). The 
results from the current study provide further evidence that tumor intracellular acidification may 
provide a benefit for cancer control and treatment.  
The current study has several limitations that should be considered. First, the number of 
animals used was small.  However, as in previous studies by our group, the effect sizes are large, 
and the ROI based pH measurements have low variability.  Also, the test-retest design reduces 
inter-subject variation. Therefore, the animal numbers used were sufficient to determine whether 
the drug combination could produce a measurable pH effect. Second, we did not optimize the 
combination dose in the current study, only one dose of drugs was examined. Future studies 
should determine whether higher doses of these drugs could produce a greater effect, or if a 
76 
 
 
similar effect would be produced with lower doses, decreasing the risk of potential side effects.  
It should also be established whether the effect is repeatable after multiple exposures and 
whether the treatment would be more effective is started earlier on in the development of the 
tumor.  The timing and dose of glucose supplementation to increase cellular metabolism prior to 
drug injection should be studied to optimize intracellular acidification, and consequently cancer 
cell death.  Future studies should also examine whether chronic intracellular acidification could 
enhance the efficacy of existing chemotherapies. 
The use of CEST MRI contrast to detect changes in intracellular pH has many potential clinical 
applications in cancer detection and treatment evaluation (8,14,157). The results of the current 
study further demonstrate that acute CEST MRI contrast changes after administration of several 
drugs in combination with glucose could help localize brain cancer by rapidly and selectively 
inducing a shift in intracellular pH. The current study demonstrated that the magnitude of 
intracellular acidification (AACID) of the tumor after combined drug injection was larger when 
providing glucose as a substrate. 
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                                            Chapter 5  
5   Conclusions and Future Directions  
 
5.1   Summary of Findings  
The overall goal of the work presented in this thesis was to maximize intracellular tumor 
acidification following drug treatment.  In the first study, one hour after DCA intravenous 
injection (200 mg/kg) there was a significant increase in tumor AACID level by 0.04±0.01 
corresponding to a 0.16 decrease in pHi, and no change in AACID in contralateral tissue. In the 
second study presented, two hours after cariporide intraperitoneal injection there was a 
significant 0.12±0.03 increase in tumor AACID value corresponding to a 0.48 decrease in pHi, 
and no change in AACID value in contralateral tissue.  Finally, in the last study presented, two 
hours after combination drug intraperitoneal injection there was a significant 0.10±0.03 increase 
in tumor AACID corresponding to a 0.40 decrease in pHi. After injecting the drug combination 
with glucose the AACID value decreased by 0.18±0.03 corresponding to a 0.72 decrease in pHi. 
AACID values were unchanged in contralateral tissue. The results of the current study further 
demonstrate that acute CEST MRI contrast changes after administration of several drugs in 
combination with glucose could help localize brain cancer by rapidly and selectively inducing a 
shift in intracellular pH. We designed a combination therapy to simultaneously target these five 
pH regulatory mechanisms using drugs already approved for human use including quercetin, 
pantoprazole (PPZ), acetazolamide, dichloroacetate (DCA), and cariporide. The current study 
demonstrated that the magnitude of intracellular acidification (AACID) of the tumor after 
combined drug injection was larger when providing glucose as a substrate. 
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5.2   Limitations  
There are several limitations to the current work that should be considered. 
1. The number of animals used was small.  However, as in previous studies by our group, the 
effect sizes are large, and the ROI based pH measurements have low variability. Also, the test-
retest design reduces inter-subject variation. Therefore, the animal numbers used were sufficient 
to determine whether the drugs could produce a measurable pH effect. 
2.  Cariporide and quercetin at the doses studied cannot be dissolved in distilled water or PBS. 
Therefore, these drugs were dissolved in DMSO. DMSO alone caused a small increase in 
AACID value suggesting a decrease in intracellular pH. This could be considered an advantage 
for studies aimed at lowering intracellular pH, as long as the concentration of DMSO is 
sufficiently small to limit any toxic effects. 
3. We did not optimize the combination drug doses in the current study, only one dose of drugs 
was examined. Future studies should determine whether higher doses of these drugs could 
produce a greater effect, or if a similar effect would be produced with lower doses, decreasing 
the risk of potential side effects.  It should also be established whether the effect is repeatable 
after multiple exposures and whether the treatment would be more effective is started earlier on 
in the development of the tumor.  The timing and dose of glucose supplementation to increase 
cellular metabolism prior to drug injection should be studied to optimize intracellular 
acidification, and consequently cancer cell death. We only studied one animal model in cancer, 
also, we do not have a calibration of AACID measurement within tumors to make absolute pH 
measurements. Future studies should also examine whether chronic intracellular acidification 
could enhance the efficacy of existing chemotherapies. 
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5.3   Conclusion 
The use of CEST MRI contrast to detect changes in intracellular pH has many potential clinical 
applications in cancer detection and treatment evaluation (8,14,157). The results of the current 
study further demonstrate that acute CEST MRI contrast changes (86,89,187,204) after 
administration of several drugs in combination with glucose could help localize brain cancer by 
rapidly and selectively inducing a shift in intracellular pH. The current study demonstrated that 
the magnitude of intracellular acidification (AACID) of the tumor after combined drug injection 
was larger when providing glucose as a substrate could help localize brain cancer by rapidly and 
selectively inducing a shift in intracellular pH. Since the drugs are approved for use in humans, 
future studies in people with glioblastoma should be performed to determine whether 
pharmacologic modulation of tumor pH would aid in cancer localization. 
 
5.4   Future directions  
This thesis studied the effect of the MCT and V-ATPases inhibitor dichloroacetate, Na+/H+ 
exchange inhibitor cariporide, and a combination therapy to simultaneously target five pH 
regulatory mechanisms using mostly drugs approved for human use including quercetin, 
pantoprazole (PPZ), acetazolamide, and dichloroacetate (DCA).  
We did not optimize the combination dose in the current study, only one dose of drugs was 
examined. Future studies should determine whether higher doses of these drugs could produce a 
greater effect, or if a similar effect would be produced with lower doses, decreasing the risk of 
potential side effects.  It should also be established whether the effect is repeatable after multiple 
exposures. 
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Also, future work should evaluate the effect of these drugs on tumor pHi and determine which 
combination of drugs cause the greatest decrease in pHi with therapeutic dosages. Also, to design 
experiments to observe the effects of these drug combinations on tumor growth and optimize the 
dose for maximum growth delay and enhancement of the efficacy of chemotherapy drugs. 
Also, it is interesting to design experiments to measure pHe along with pHi (185) to monitor the 
effect on extracellular-intracellular pH, as it is the pH gradient across the plasma membrane that 
impacts the efficacy of chemotherapy drugs. This simultaneous measurement of pH gradient may 
help to design the most effective treatment regime. Most recently, contributed to a published 
study of longitudinal measurement of the intracellular/extracellular pH gradient in a rat glioma 
model using MRI. pHi was mapped using CEST MRI, whereas regional pHe was determined 
using hyperpolarized 13C bicarbonate magnetic resonance spectroscopic imaging at 3 Tesla 
(185). 
The results from this study indicate the potential value of carbonic anhydrase inhibitors in tumor 
acidification and hopefully will stimulate future experiments to expand the role of such drugs in 
cancer treatment. 
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